Login Register Cart 0
Generic placeholder image

Current Medicinal Chemistry

Editor-in-Chief

ISSN (Print): 0929-8673
ISSN (Online): 1875-533X

Back
Journal Home About Journal Editorial Board Journal Insight Current Issue Volumes/Issues
Subscribe Translate in Chinese
Review Article

Translational Theragnosis of Ovarian Cancer: where do we stand?

Author(s): Maria Grazia Perrone, Oreste Luisi, Anna De Grassi, Savina Ferorelli, Gennaro Cormio and Antonio Scilimati*

Volume 27, Issue 34, 2020

Page: [5675 - 5715] Pages: 41

DOI: 10.2174/0929867326666190816232330

Price: $65

Abstract

Background: Ovarian cancer is the second most common gynecologic malignancy, accounting for approximately 220,000 deaths annually worldwide. Despite radical surgery and initial high response rates to platinum- and taxane-based chemotherapy, most patients experience a relapse, with a median progression-free survival of only 18 months. Overall survival is approximately 30% at 5 years from the diagnosis. In comparison, patients out from breast cancer are more than 80 % after ten years from the disease discovery. In spite of a large number of published fundamental and applied research, and clinical trials, novel therapies are urgently needed to improve outcomes of the ovarian cancer. The success of new drugs development in ovarian cancer will strongly depend on both fully genomic disease characterization and, then, availability of biomarkers able to identify women likely to benefit from a given new therapy.

Methods: In this review, the focus is given to describe how complex is the diseases under the simple name of ovarian cancer, in terms of cell tumor types, histotypes, subtypes, and specific gene mutation or differently expressed in the tumor with respect the healthy ovary. The first- and second-line pharmacological treatment clinically used over the last fifty years are also described. Noteworthy achievements in vitro and in vivo tested new drugs are also summarized. Recent literature related to up to date ovarian cancer knowledge, its detection by biomarkers and chemotherapy was searched from several articles on Pubmed, Google Scholar, MEDLINE and various Governmental Agencies till April 2019.

Results: The papers referenced by this review allow a deep analysis of status of the art in the classification of the several types of ovarian cancer, the present knowledge of diagnosis based on biomarkers and imaging techniques, and the therapies developed over the past five decades.

Conclusion: This review aims at stimulating more multi-disciplinary efforts to identify a panel of novel and more specific biomarkers to be used to screen patients for a very early diagnosis, to have prognosis and therapy efficacy indications. The desired final goal would be to have available tools allowing to reduce the recurrence rate, increase both the disease progression free interval and of course the overall survival at five years from the diagnosis that today is still very low.

Keywords: Ovarian cancer, histotypes, FIGO and AJCC classification, diagnosis, surgical and drug treatment, biomarkers, epigenetic, perspectives.

« Previous Next »
[1]
Kim, S.; Han, Y.; Kim, S.I.; Kim, H-S.; Kim, S.J.; Song, Y.S. Tumor evolution and chemoresistance in ovarian cancer. NPJ Precis Oncol, 2018, 2(20), 20.
[http://dx.doi.org/10.1038/s41698-018-0063-0 ] [PMID: 30246154]
[2]
Wei, W.; Dizon, D.; Vathipadiekal, V.; Birrer, M.J. Ovarian cancer: genomic analysis. Ann. Oncol., 2013, 24(10)(Suppl. 10), x7-x15.
[http://dx.doi.org/10.1093/annonc/mdt462 ] [PMID: 24265410]
[3]
Lozano, R.; Naghavi, M.; Foreman, K.; Lim, S.; Shibuya, K.; Aboyans, V.; Abraham, J.; Adair, T.; Aggarwal, R.; Ahn, S.Y.; Alvarado, M.; Anderson, H.R.; Anderson, L.M.; Andrews, K.G.; Atkinson, C.; Baddour, L.M.; Barker-Collo, S.; Bartels, D.H.; Bell, M.L.; Benjamin, E.J.; Bennett, D.; Bhalla, K.; Bikbov, B.; Bin Abdulhak, A.; Birbeck, G.; Blyth, F.; Bolliger, I.; Boufous, S.; Bucello, C.; Burch, M.; Burney, P.; Carapetis, J.; Chen, H.; Chou, D.; Chugh, S.S.; Coffeng, L.E.; Colan, S.D.; Colquhoun, S.; Colson, K.E.; Condon, J.; Connor, M.D.; Cooper, L.T.; Corriere, M.; Cortinovis, M.; de Vaccaro, K.C.; Couser, W.; Cowie, B.C.; Criqui, M.H.; Cross, M.; Dabhadkar, K.C.; Dahodwala, N.; De Leo, D.; Degenhardt, L.; Delossantos, A.; Denenberg, J.; Des Jarlais, D.C.; Dharmaratne, S.D.; Dorsey, E.R.; Driscoll, T.; Duber, H.; Ebel, B.; Erwin, P.J.; Espindola, P.; Ezzati, M.; Feigin, V.; Flaxman, A.D.; Forouzanfar, M.H.; Fowkes, F.G.; Franklin, R.; Fransen, M.; Freeman, M.K.; Gabriel, S.E.; Gakidou, E.; Gaspari, F.; Gillum, R.F.; Gonzalez-Medina, D.; Halasa, Y.A.; Haring, D.; Harrison, J.E.; Havmoeller, R.; Hay, R.J.; Hoen, B.; Hotez, P.J.; Hoy, D.; Jacobsen, K.H.; James, S.L.; Jasrasaria, R.; Jayaraman, S.; Johns, N.; Karthikeyan, G.; Kassebaum, N.; Keren, A.; Khoo, J.P.; Knowlton, L.M.; Kobusingye, O.; Koranteng, A.; Krishnamurthi, R.; Lipnick, M.; Lipshultz, S.E.; Ohno, S.L.; Mabweijano, J.; MacIntyre, M.F.; Mallinger, L.; March, L.; Marks, G.B.; Marks, R.; Matsumori, A.; Matzopoulos, R.; Mayosi, B.M.; McAnulty, J.H.; McDermott, M.M.; McGrath, J.; Mensah, G.A.; Merriman, T.R.; Michaud, C.; Miller, M.; Miller, T.R.; Mock, C.; Mocumbi, A.O.; Mokdad, A.A.; Moran, A.; Mulholland, K.; Nair, M.N.; Naldi, L.; Narayan, K.M.; Nasseri, K.; Norman, P.; O’Donnell, M.; Omer, S.B.; Ortblad, K.; Osborne, R.; Ozgediz, D.; Pahari, B.; Pandian, J.D.; Rivero, A.P.; Padilla, R.P.; Perez-Ruiz, F.; Perico, N.; Phillips, D.; Pierce, K.; Pope, C.A., III; Porrini, E.; Pourmalek, F.; Raju, M.; Ranganathan, D.; Rehm, J.T.; Rein, D.B.; Remuzzi, G.; Rivara, F.P.; Roberts, T.; De León, F.R.; Rosenfeld, L.C.; Rushton, L.; Sacco, R.L.; Salomon, J.A.; Sampson, U.; Sanman, E.; Schwebel, D.C.; Segui-Gomez, M.; Shepard, D.S.; Singh, D.; Singleton, J.; Sliwa, K.; Smith, E.; Steer, A.; Taylor, J.A.; Thomas, B.; Tleyjeh, I.M.; Towbin, J.A.; Truelsen, T.; Undurraga, E.A.; Venketasubramanian, N.; Vijayakumar, L.; Vos, T.; Wagner, G.R.; Wang, M.; Wang, W.; Watt, K.; Weinstock, M.A.; Weintraub, R.; Wilkinson, J.D.; Woolf, A.D.; Wulf, S.; Yeh, P.H.; Yip, P.; Zabetian, A.; Zheng, Z.J.; Lopez, A.D.; Murray, C.J.; AlMazroa, M.A.; Memish, Z.A. Global and regional mortality from 235 causes of death for 20 age groups in 1990 and 2010: a systematic analysis for the Global Burden of Disease Study 2010. Lancet, 2012, 380(9859), 2095-2128.
[http://dx.doi.org/10.1016/S0140-6736(12)61728-0 ] [PMID: 23245604]
[4]
Chornokur, G.; Amankwah, E.K.; Schildkraut, J.M.; Phelan, C.M. Global ovarian cancer health disparities. Gynecol. Oncol., 2013, 129(1), 258-264.
[http://dx.doi.org/10.1016/j.ygyno.2012.12.016 ] [PMID: 23266352]
[5]
Cronen, P.W.; Nagaraj, H.S. Ovarian tumors in children. South. Med. J., 1988, 81(4), 464-468.
[http://dx.doi.org/10.1097/00007611-198804000-00014 ] [PMID: 2833818]
[6]
Sadeghian, N.; Sadeghian, I.; Mirshemirani, A.; Khaleghnejad Tabari, A.; Ghoroubi, J.; Abdollah Gorji, F.; Roushanzamir, F. Types and frequency of ovarian masses in children over a 10-year period. Caspian J. Intern. Med., 2015, 6(4), 220-223.
[PMID: 26644896]
[7]
Zhang, M.; Jiang, W.; Li, G.; Xu, C. Ovarian masses in children and adolescents - an analysis of 521 clinical cases. J. Pediatr. Adolesc. Gynecol., 2014, 27(3), e73-e77.
[http://dx.doi.org/10.1016/j.jpag.2013.07.007 ] [PMID: 24157281]
[8]
Montes, A.F.; Gomez, J.G.; Viejo, M.N.; Bermejo, M.A.; Urrutia, S.A.; Mata, J.G. Epidemiology and etiology of ovarian cancer in: Ovarian Cancer - Basic Science Perspective, Dr. Samir Farghaly (Ed.); Intech Open, 2012.
[9]
Dong, X.; Men, X.; Zhang, W.; Lei, P. Advances in tumor markers of ovarian cancer for early diagnosis. Indian J. Cancer, 2014, 51(Suppl. 3), e72-e76.
[http://dx.doi.org/10.4103/0019-509X.154049 ] [PMID: 25818738]
[10]
Shunmugam, D.; Shanmugasundaram, S.; Gandhi, A. Rare cause of ovarian mass. BMJ Case Rep., 2018, 2018, bcr-2018-bcr-225564.
[PMID: 30232202]
[11]
Visvanathan, K.; Shaw, P.; May, B.J.; Bahadirli-Talbott, A.; Kaushiva, A.; Risch, H.; Narod, S.; Wang, T.L.; Parkash, V.; Vang, R.; Levine, D.A.; Soslow, R.; Kurman, R.; Shih, I.M. Fallopian tube lesions in women at high risk for ovarian cancer: a multicenter study. Cancer Prev. Res. (Phila.), 2018, 11(11), 697-706.
[http://dx.doi.org/10.1158/1940-6207.CAPR-18-0009 ] [PMID: 30232083]
[12]
Colombo, N.; Peiretti, M.; Castiglione, M. ESMO guidelines working group. Non-epithelial ovarian cancer: ESMO clinical recommendations for diagnosis, treatment and follow-up. Ann. Oncol., 2009, 20(Suppl. 4), 24-26.
[http://dx.doi.org/10.1093/annonc/mdp118 ] [PMID: 19454453]
[13]
del Carmen, M.G.; Birrer, M.; Schorge, J.O. Carcinosarcoma of the ovary: a review of the literature. Gynecol. Oncol., 2012, 125(1), 271-277.
[http://dx.doi.org/10.1016/j.ygyno.2011.12.418 ] [PMID: 22155675]
[14]
Lengyel, E. Ovarian cancer development and metastasis. Am. J. Pathol., 2010, 177(3), 1053-1064.
[http://dx.doi.org/10.2353/ajpath.2010.100105 ] [PMID: 20651229]
[15]
Bast, R.C., Jr; Hennessy, B.; Mills, G.B. The biology of ovarian cancer: new opportunities for translation. Nat. Rev. Cancer, 2009, 9(6), 415-428.
[http://dx.doi.org/10.1038/nrc2644 ] [PMID: 19461667]
[16]
Vaughan, S.; Coward, J.I.; Bast, R.C., Jr; Berchuck, A.; Berek, J.S.; Brenton, J.D.; Coukos, G.; Crum, C.C.; Drapkin, R.; Etemadmoghadam, D.; Friedlander, M.; Gabra, H.; Kaye, S.B.; Lord, C.J.; Lengyel, E.; Levine, D.A.; McNeish, I.A.; Menon, U.; Mills, G.B.; Nephew, K.P.; Oza, A.M.; Sood, A.K.; Stronach, E.A.; Walczak, H.; Bowtell, D.D.; Balkwill, F.R. Rethinking ovarian cancer: recommendations for improving outcomes. Nat. Rev. Cancer, 2011, 11(10), 719-725.
[http://dx.doi.org/10.1038/nrc3144 ] [PMID: 21941283]
[17]
Leong, H.S.; Galletta, L.; Etemadmoghadam, D.; George, J.; Köbel, M.; Ramus, S.J.; Bowtell, D. Australian ovarian cancer study. Efficient molecular subtype classification of high-grade serous ovarian cancer. J. Pathol., 2015, 236(3), 272-277.
[http://dx.doi.org/10.1002/path.4536 ] [PMID: 25810134]
[18]
Cancer genome atlas research network. Integrated genomic analyses of ovarian carcinoma. Nature, 2011, 474(7353), 609-615.
[http://dx.doi.org/10.1038/nature10166 ] [PMID: 21720365]
[19]
Konecny, G.E.; Wang, C.; Hamidi, H.; Winterhoff, B.; Kalli, K.R.; Dering, J.; Ginther, C.; Chen, H.W.; Dowdy, S.; Cliby, W.; Gostout, B.; Podratz, K.C.; Keeney, G.; Wang, H.J.; Hartmann, L.C.; Slamon, D.J.; Goode, E.L. Prognostic and therapeutic relevance of molecular subtypes in high-grade serous ovarian cancer. J. Natl. Cancer Inst., 2014, 106(10)dju249
[http://dx.doi.org/10.1093/jnci/dju249 ] [PMID: 25269487]
[20]
FIGO Committee on Gynecologic Oncology. Benedet, J.L.; Bender, H.; Jones III H.; Ngan, H.Y.S.; Pecorelli S. FIGO staging classifications and clinical practice guidelines in the management of gynecologic cancers. Int. J. Gynaecol. Obstet., 2000, 70, 209-262.
[http://dx.doi.org/10.1016/S0020-7292(00)90001-8]
[21]
Prat, J. FIGO Committee on Gynecologic Oncology. Staging classification for cancer of the ovary, fallopian tube, and peri-toneum. Int. J. Gynaecol. Obstet., 2014, 124(1), 1-5.
[http://dx.doi.org/10.1016/j.ijgo.2013.10.001 ] [PMID: 24219974]
[22]
Kurman, R.J.; Shih, IeM. Molecular pathogenesis and extraovarian origin of epithelial ovarian cancer--shifting the paradigm. Hum. Pathol., 2011, 42(7), 918-931.
[http://dx.doi.org/10.1016/j.humpath.2011.03.003 ] [PMID: 21683865]
[23]
Banerjee, S.; Kaye, S.B. New strategies in the treatment of ovarian cancer: current clinical perspectives and future potential. Clin. Cancer Res., 2013, 19(5), 961-968.
[http://dx.doi.org/10.1158/1078-0432.CCR-12-2243 ] [PMID: 23307860]
[24]
Singer, G.; Oldt, R., III; Cohen, Y.; Wang, B.G.; Sidransky, D.; Kurman, R.J.; Shih, IeM. Mutations in BRAF and KRAS characterize the development of low-grade ovarian serous carcinoma. J. Natl. Cancer Inst., 2003, 95(6), 484-486.
[http://dx.doi.org/10.1093/jnci/95.6.484 ] [PMID: 12644542]
[25]
Wiegand, K.C.; Shah, S.P.; Al-Agha, O.M.; Zhao, Y.; Tse, K.; Zeng, T.; Senz, J.; McConechy, M.K.; Anglesio, M.S.; Kalloger, S.E.; Yang, W.; Heravi-Moussavi, A.; Giuliany, R.; Chow, C.; Fee, J.; Zayed, A.; Prentice, L.; Melnyk, N.; Turashvili, G.; Delaney, A.D.; Madore, J.; Yip, S.; McPherson, A.W.; Ha, G.; Bell, L.; Fereday, S.; Tam, A.; Galletta, L.; Tonin, P.N.; Provencher, D.; Miller, D.; Jones, S.J.; Moore, R.A.; Morin, G.B.; Oloumi, A.; Boyd, N.; Aparicio, S.A.; Shih, IeM.; Mes-Masson, A.M.; Bowtell, D.D.; Hirst, M.; Gilks, B.; Marra, M.A.; Huntsman, D.G. ARID1A mutations in endometriosis-associated ovarian carcinomas. N. Engl. J. Med., 2010, 363(16), 1532-1543.
[http://dx.doi.org/10.1056/NEJMoa1008433 ] [PMID: 20942669]
[26]
Heravi-Moussavi, A.; Anglesio, M.S.; Cheng, S.W.; Senz, J.; Yang, W.; Prentice, L.; Fejes, A.P.; Chow, C.; Tone, A.; Kalloger, S.E.; Hamel, N.; Roth, A.; Ha, G.; Wan, A.N.; Maines-Bandiera, S.; Salamanca, C.; Pasini, B.; Clarke, B.A.; Lee, A.F.; Lee, C.H.; Zhao, C.; Young, R.H.; Aparicio, S.A.; Sorensen, P.H.; Woo, M.M.; Boyd, N.; Jones, S.J.; Hirst, M.; Marra, M.A.; Gilks, B.; Shah, S.P.; Foulkes, W.D.; Morin, G.B.; Huntsman, D.G. Recurrent somatic DICER1 mutations in nonepithelial ovarian cancers. N. Engl. J. Med., 2012, 366(3), 234-242.
[http://dx.doi.org/10.1056/NEJMoa1102903 ] [PMID: 22187960]
[27]
McConechy, M.K.; Anglesio, M.S.; Kalloger, S.E.; Yang, W.; Senz, J.; Chow, C.; Heravi-Moussavi, A.; Morin, G.B.; Mes-Masson, A.M.; Carey, M.S.; McAlpine, J.N.; Kwon, J.S.; Prentice, L.M.; Boyd, N.; Shah, S.P.; Gilks, C.B.; Huntsman, D.G. Australian ovarian cancer study group. Subtype-specific mutation of PPP2R1A in endometrial and ovarian carcinomas. J. Pathol., 2011, 223(5), 567-573.
[http://dx.doi.org/10.1002/path.2848 ] [PMID: 21381030]
[28]
Al-Agha, O.M.; Huwait, H.F.; Chow, C.; Yang, W.; Senz, J.; Kalloger, S.E.; Huntsman, D.G.; Young, R.H.; Gilks, C.B. FOXL2 is a sensitive and specific marker for sex cord-stromal tumors of the ovary. Am. J. Surg. Pathol., 2011, 35(4), 484-494.
[http://dx.doi.org/10.1097/PAS.0b013e31820a406c ] [PMID: 21378549]
[29]
Berns, E.M.; Bowtell, D.D. The changing view of high-grade serous ovarian cancer. Cancer Res., 2012, 72(11), 2701-2704.
[http://dx.doi.org/10.1158/0008-5472.CAN-11-3911 ] [PMID: 22593197]
[30]
Lu, F.I.; Gilks, C.B.; Mulligan, A.M.; Ryan, P.; Allo, G.; Sy, K.; Shaw, P.A.; Pollett, A.; Clarke, B.A. Prevalence of loss of expression of DNA mismatch repair proteins in primary epithelial ovarian tumors. Int. J. Gynecol. Pathol., 2012, 31(6), 524-531.
[http://dx.doi.org/10.1097/PGP.0b013e31824fe2aa ] [PMID: 23018216]
[31]
Catasús, L.; Bussaglia, E.; Rodrguez, I.; Gallardo, A.; Pons, C.; Irving, J.A.; Prat, J. Molecular genetic alterations in endometrioid carcinomas of the ovary: similar frequency of beta-catenin abnormalities but lower rate of microsatellite instability and PTEN alterations than in uterine endometrioid carcinomas. Hum. Pathol., 2004, 35(11), 1360-1368.
[http://dx.doi.org/10.1016/j.humpath.2004.07.019 ] [PMID: 15668893]
[32]
Vang, R.; Shih, IeM.; Kurman, R.J. Ovarian low-grade and high-grade serous carcinoma: pathogenesis, clinicopathologic and molecular biologic features, and diagnostic problems. Adv. Anat. Pathol., 2009, 16(5), 267-282.
[http://dx.doi.org/10.1097/PAP.0b013e3181b4fffa ] [PMID: 19700937]
[33]
Elezaby, M.; Lees, B.; Maturen, K.E.; Barroilhet, L.; Wisinski, K.B.; Schrager, S.; Wilke, L.G.; Sadowski, E. BRCA mutation carriers: breast and ovarian cancer screening guidelines and imaging considerations. Radiology, 2019, 291(3), 554-569.
[http://dx.doi.org/10.1148/radiol.2019181814 ] [PMID: 31038410]
[34]
Sangha, N.; Wu, R.; Kuick, R.; Powers, S.; Mu, D.; Fiander, D.; Yuen, K.; Katabuchi, H.; Tashiro, H.; Fearon, E.R.; Cho, K.R. . Neurofibromin 1 (NF1) defects are common in human ovarian serous carcinomas and co-occur with TP53 mutations. Neoplasia, 2008, 10(12), 1362-1372, 1372..
[http://dx.doi.org/10.1593/neo.08784] [PMID: 19048115]
[35]
Peng, G.; Mills, G.B. Surviving ovarian cancer: an affair between defective DNA repair and RB1. Clin. Cancer Res., 2018, 24(3), 508-510.
[http://dx.doi.org/10.1158/1078-0432.CCR-17-3022 ] [PMID: 29191971]
[36]
La Vecchia, C. Ovarian cancer: epidemiology and risk factors. Eur. J. Cancer Prev., 2017, 26(1), 55-62.
[http://dx.doi.org/10.1097/CEJ.0000000000000217 ] [PMID: 26731563]
[37]
Ogishima, J.; Taguchi, A.; Kawata, A.; Kawana, K.; Yoshida, M.; Yoshimatsu, Y.; Sato, M.; Nakamura, H.; Kawata, Y.; Nishijima, A.; Fujimoto, A.; Tomio, K.; Adachi, K.; Nagamatsu, T.; Oda, K.; Kiyono, T.; Osuga, Y.; Fujii, T. The oncogene KRAS promotes cancer cell dissemination by stabilizing spheroid formation via the MEK pathway. BMC Cancer, 2018, 18(1), 1201.
[http://dx.doi.org/10.1186/s12885-018-4922-4 ] [PMID: 30509235]
[38]
Lassus, H.; Sihto, H.; Leminen, A.; Joensuu, H.; Isola, J.; Nupponen, N.N.; Butzow, R. Gene amplification, mutation, and protein expression of EGFR and mutations of ERBB2 in serous ovarian carcinoma. J. Mol. Med. (Berl.), 2006, 84(8), 671-681.
[http://dx.doi.org/10.1007/s00109-006-0054-4 ] [PMID: 16607561]
[39]
Hájková, N.; Tichá, I.; Hojný, J.; Němejcová, K.; Bártů, M.; Michálková, R.; Zikán, M.; Cibula, D.; Laco, J.; Geryk, T.; Méhes, G.; Dundr, P. Synchronous endometrioid endometrial and ovarian carcinomas are biologically related: A clinico-pathological and molecular (next generation sequencing) study of 22 cases. Oncol. Lett., 2019, 17(2), 2207-2214.
[PMID: 30675285]
[40]
Su, Y.F.; Tsai, E.M.; Chen, C.C.; Wu, C.C.; Er, T.K. Targeted sequencing of a specific gene panel detects a high frequency of ARID1A and PIK3CA mutations in ovarian clear cell carcinoma. Clin. Chim. Acta, 2019, 494, 1-7.
[http://dx.doi.org/10.1016/j.cca.2019.03.003 ] [PMID: 30851247]
[41]
Terakawa, J.; Serna, V.A.; Taketo, M.M.; Daikoku, T.; Suarez, A.A.; Kurita, T. Ovarian insufficiency and CTNNB1 mutations drive malignant transformation of endometrial hyperplasia with altered PTEN/PI3K activities. Proc. Natl. Acad. Sci. USA, 2019, 116(10), 4528-4537.
[http://dx.doi.org/10.1073/pnas.1814506116 ] [PMID: 30782821]
[42]
Karnezis, A.N.; Wang, Y.; Keul, J.; Tessier-Cloutier, B.; Magrill, J.; Kommoss, S.; Senz, J.; Yang, W.; Proctor, L.; Schmidt, D.; Clement, P.B.; Gilks, C.B.; Huntsman, D.G.; Kommoss, F. DICER1 and FOXL2 mutation status correlates with clinicopathologic features in ovarian sertoli-leydig cell tumors. Am. J. Surg. Pathol., 2019, 43(5), 628-638.
[http://dx.doi.org/10.1097/PAS.0000000000001232 ] [PMID: 30986800]
[43]
Wang, X.; Chen, H.; Wen, Y.; Yang, X.; Han, Q.; Jiang, P.; Huang, Z.; Cai, J.; Wang, Z. Dicer affects cisplatinmediated apoptosis in epithelial ovarian cancer cells. Mol. Med. Rep., 2018, 18(5), 4381-4387.
[http://dx.doi.org/10.3892/mmr.2018.9452 ] [PMID: 30221734]
[44]
Robertson, J.C.; Jorcyk, C.L.; Oxford, J.T. DICER1 syndrome: DICER1 mutations in rare cancers. Cancers (Basel), 2018, 10(5), 2-17.
[http://dx.doi.org/10.3390/cancers10050143 ] [PMID: 29762508]
[45]
Wang, F.; Zou, Y.; Liu, F.Y.; Yu, X.H.; Huang, H.; Zhang, N.; Qi, Y.Y.; Liu, R.F.; Liu, X.Y.; Chen, J.; Huang, O.P.; He, M. Infrequent mutations of the PPP2R1A and PPP2R1B genes in patients with ovarian cancer. Mol. Med. Rep., 2013, 7(6), 1826-1830.
[http://dx.doi.org/10.3892/mmr.2013.1416 ] [PMID: 23588898]
[46]
Wang, Y.Q.; Wang, P.Y.; Wang, Y.T.; Yang, G.F.; Zhang, A.; Miao, Z.H. An update on Poly(ADP-ribose) polymerase-1 (PARP-1) inhibitors: opportunities and challenges in can-cer therapy. J. Med. Chem., 2016, 59(21), 9575-9598.
[http://dx.doi.org/10.1021/acs.jmedchem.6b00055 ] [PMID: 27416328]
[47]
Martin, V.R. Straight talk about ovarian cancer. Nursing, 2005, 35(4), 36-41.
[http://dx.doi.org/10.1097/00152193-200504000-00035 ] [PMID: 15818250]
[48]
Wilson, A.J.; Fadare, O.; Beeghly-Fadiel, A.; Son, D.S.; Liu, Q.; Zhao, S.; Saskowski, J.; Uddin, M.J.; Daniel, C.; Crews, B.; Lehmann, B.D.; Pietenpol, J.A.; Crispens, M.A.; Marnett, L.J.; Khabele, D. Aberrant over-expression of COX-1 intersects multiple pro-tumorigenic pathways in high-grade serous ovarian cancer. Oncotarget, 2015, 6(25), 21353-21368.
[http://dx.doi.org/10.18632/oncotarget.3860 ] [PMID: 25972361]
[49]
Lahmann, P.H.; Cust, A.E.; Friedenreich, C.M.; Schulz, M.; Lukanova, A.; Kaaks, R.; Lundin, E.; Tjønneland, A.; Halkjaer, J.; Severinsen, M.T.; Overvad, K.; Fournier, A.; Chabbert-Buffet, N.; Clavel-Chapelon, F.; Dossus, L.; Pischon, T.; Boeing, H.; Trichopoulou, A.; Lagiou, P.; Naska, A.; Palli, D.; Grioni, S.; Mattiello, A.; Tumino, R.; Sacerdote, C.; Redondo, M.L.; Jakszyn, P.; Sánchez, M.J.; Tormo, M.J.; Ardanaz, E.; Arriola, L.; Manjer, J.; Jirström, K.; Bueno-de-Mesquita, H.B.; May, A.M.; Peeters, P.H.; Onland-Moret, N.C.; Bingham, S.; Khaw, K.T.; Allen, N.E.; Spencer, E.; Rinaldi, S.; Slimani, N.; Chajes, V.; Michaud, D.; Norat, T.; Riboli, E. Anthropometric measures and epithelial ovarian cancer risk in the European Prospective Investigation into Cancer and Nutrition. Int. J. Cancer, 2010, 126(10), 2404-2415.
[PMID: 19821492]
[50]
Lee, A.W.; Tyrer, J.P.; Doherty, J.A.; Stram, D.A.; Kupr-yjanczyk, J.; Dansonka-Mieszkowska, A.; Plisiecka-Halasa, J.; Spiewankiewicz, B.; Myers, E.J.; Chenevix-Trench, G.; Fasching, P.A.; Beckmann, M.W.; Ekici, A.B.; Hein, A.; Vergote, I.; Van Nieuwenhuysen, E.; Lambrechts, D.; Wick-lund, K.G.; Eilber, U.; Wang-Gohrke, S.; Chang-Claude, J.; Rudolph, A.; Sucheston-Campbell, L.; Odunsi, K.; Moysich, K.B.; Shvetsov, Y.B.; Thompson, P.J.; Goodman, M.T.; Wilkens, L.R.; Dörk, T.; Hillemanns, P.; Dürst, M.; Runne-baum, I.B.; Bogdanova, N.; Pelttari, L.M.; Nevanlinna, H.; Leminen, A.; Edwards, R.P.; Kelley, J.L.; Harter, P.; Schwaab, I.; Heitz, F.; du Bois, A.; Orsulic, S.; Lester, J.; Walsh, C.; Karlan, B.Y.; Hogdall, E.; Kjaer, S.K.; Jensen, A.; Vierkant, R.A.; Cunningham, J.M.; Goode, E.L.; Fridley, B.L.; Southey, M.C.; Giles, G.G.; Bruinsma, F.; Wu, X.; Hildebrandt, M.A.; Lu, K.; Liang, D.; Bisogna, M.; Levine, D.A.; Weber, R.P.; Schildkraut, J.M.; Iversen, E.S.; Ber-chuck, A.; Terry, K.L.; Cramer, D.W.; Tworoger, S.S.; Poole, E.M.; Olson, S.H.; Orlow, I.; Bandera, E.V.; Bjorge, L.; Tangen, I.L.; Salvesen, H.B.; Krakstad, C.; Massuger, L.F.; Kiemeney, L.A.; Aben, K.K.; van Altena, A.M.; Bean, Y.; Pejovic, T.; Kellar, M.; Le, N.D.; Cook, L.S.; Kelemen, L.E.; Brooks-Wilson, A.; Lubinski, J.; Gronwald, J.; Cybul-ski, C.; Jakubowska, A.; Wentzensen, N.; Brinton, L.A.; Lissowska, J.; Yang, H.; Nedergaard, L.; Lundvall, L.; Hog-dall, C.; Song, H.; Campbell, I.G.; Eccles, D.; Glasspool, R.; Siddiqui, N.; Carty, K.; Paul, J.; McNeish, I.A.; Sieh, W.; McGuire, V.; Rothstein, J.H.; Whittemore, A.S.; McLaugh-lin, J.R.; Risch, H.A.; Phelan, C.M.; Anton-Culver, H.; Zi-ogas, A.; Menon, U.; Ramus, S.J.; Gentry-Maharaj, A.; Har-rington, P.; Pike, M.C.; Modugno, F.; Rossing, M.A.; Ness, R.B.; Pharoah, P.D.; Stram, D.O.; Wu, A.H.; Pearce, C.L. Australian cancer study (ovarian cancer); Australian ovarian cancer study group. Evaluating the ovarian cancer gon-adotropin hypothesis: a candidate gene study. Gynecol. Oncol., 2015, 136(3), 542-548.
[http://dx.doi.org/10.1016/j.ygyno.2014.12.017 ] [PMID: 25528498]
[51]
Fathalla, M.F. Incessant ovulation and ovarian cancer - a hypothesis re-visited. Facts Views Vis. ObGyn, 2013, 5(4), 292-297.
[PMID: 24753957]
[52]
Testa, U.; Petrucci, E.; Pasquini, L.; Castelli, G.; Pelosi, E. Ovarian Cancers: genetic abnormalities, tumor heterogeneity and progression, clonal evolution and cancer stem cells. Medicines (Basel), 2018, 5(1), 1-74.
[http://dx.doi.org/10.3390/medicines5010016 ] [PMID: 29389895]
[53]
Yang, H.P.; Murphy, K.R.; Pfeiffer, R.M.; George, N.; Garcia-Closas, M.; Lissowska, J.; Brinton, L.A.; Wentzensen, N. Lifetime number of ovulatory cycles and risks of ovarian and endometrial cancer among postmenopausal women. Am. J. Epidemiol., 2016, 183(9), 800-814.
[http://dx.doi.org/10.1093/aje/kwv308 ] [PMID: 27190045]
[54]
Hannah, N. Pregnancy after 35: What are the risks? Available at: https://www.medicalnewstoday.com/articles/317861.php
[55]
Whiteman, D.C.; Siskind, V.; Purdie, D.M.; Green, A.C. Timing of pregnancy and the risk of epithelial ovarian cancer. Cancer Epidemiol. Biomarkers Prev., 2003, 12(1), 42-46.
[PMID: 12540502]
[56]
Sung, H.K.; Ma, S.H.; Choi, J.Y.; Hwang, Y.; Ahn, C.; Kim, B.G.; Kim, Y.M.; Kim, J.W.; Kang, S.; Kim, J.; Kim, T.J.; Yoo, K.Y.; Kang, D.; Park, S. The effect of breastfeeding duration and parity on the risk of epithelial ovarian cancer: A systematic review and meta-analysis. J. Prev. Med. Public Health, 2016, 49(6), 349-366.
[http://dx.doi.org/10.3961/jpmph.16.066 ] [PMID: 27951628]
[57]
Li, D.P.; Du, C.; Zhang, Z.M.; Li, G.X.; Yu, Z.F.; Wang, X.; Li, P.F.; Cheng, C.; Liu, Y.P.; Zhao, Y.S. Breastfeeding and ovarian cancer risk: a systematic review and meta-analysis of 40 epidemiological studies. Asian Pac. J. Cancer Prev., 2014, 15(12), 4829-4837.
[http://dx.doi.org/10.7314/APJCP.2014.15.12.4829 ] [PMID: 24998548]
[58]
Luan, N.N.; Wu, Q.J.; Gong, T.T.; Vogtmann, E.; Wang, Y.L.; Lin, B.; Lin, B. Breastfeeding and ovarian cancer risk: a meta-analysis of epidemiologic studies. Am. J. Clin. Nutr., 2013, 98(4), 1020-1031.
[http://dx.doi.org/10.3945/ajcn.113.062794 ] [PMID: 23966430]
[59]
Mørch, L.S.; Løkkegaard, E.; Andreasen, A.H.; Kjaer, S.K.; Lidegaard, O. Hormone therapy and different ovarian cancers: a national cohort study. Am. J. Epidemiol., 2012, 175(12), 1234-1242.
[http://dx.doi.org/10.1093/aje/kwr446 ] [PMID: 22517811]
[60]
Beral, V.; Doll, R.; Hermon, C.; Peto, R.; Reeves, G. Collaborative Group on Epidemiological Studies of Ovarian Cancer. Ovarian cancer and oral contraceptives: collaborative reanalysis of data from 45 epidemiological studies including 23,257 women with ovarian cancer and 87,303 controls. Lancet, 2008, 371(9609), 303-314.
[http://dx.doi.org/10.1016/S0140-6736(08)60167-1 ] [PMID: 18294997]
[61]
Mungenast, F.; Thalhammer, T. Estrogen biosynthesis and action in ovarian cancer. Front. Endocrinol. (Lausanne), 2014, 5, 192.
[http://dx.doi.org/10.3389/fendo.2014.00192 ] [PMID: 25429284]
[62]
Baber, R. Menopausal hormone therapy and ovarian cancer. J Midlife Health, 2015, 6(3), 101-103.
[http://dx.doi.org/10.4103/0976-7800.165587 ] [PMID: 26538985]
[63]
Gaitskell, K.; Green, J.; Pirie, K.; Reeves, G.; Beral, V. Million Women Study Collaborators Tubal ligation and ovarian cancer risk in a large cohort: Substantial variation by histological type. Int. J. Cancer, 2016, 138(5), 1076-1084.
[http://dx.doi.org/10.1002/ijc.29856 ] [PMID: 26378908]
[64]
Peng, M.; Zhang, H.; Jaafar, L.; Risinger, J.I.; Huang, S.; Mivechi, N.F.; Ko, L. Human ovarian cancer stroma contains luteinized theca cells harboring tumor suppressor gene GT198 mutations. J. Biol. Chem., 2013, 288(46), 33387-33397.
[http://dx.doi.org/10.1074/jbc.M113.485581 ] [PMID: 24097974]
[65]
Brilhante, A.V.; Augusto, K.L.; Portela, M.C.; Sucupira, L.C.G.; Oliveira, L.A.F.; Pouchaim, A.J.M.V.; Nóbrega, L.R.M.; Magalhães, T.F.; Sobreira, L.R.P. Endometriosis and ovarian cancer: an integrative review (endometriosis and ovarian cancer). Asian Pac. J. Cancer Prev., 2017, 18(1), 11-16.
[PMID: 28240000]
[66]
Wernli, K.J.; Newcomb, P.A.; Hampton, J.M.; Trentham-Dietz, A.; Egan, K.M. Inverse association of NSAID use and ovarian cancer in relation to oral contraceptive use and parity. Br. J. Cancer, 2008, 98(11), 1781-1783.
[http://dx.doi.org/10.1038/sj.bjc.6604392 ] [PMID: 18506182]
[67]
Liu, Z.; Zhang, T.T.; Zhao, J.J.; Qi, S.F.; Du, P.; Liu, D.W.; Tian, Q.B. The association between overweight, obesity and ovarian cancer: a meta-analysis. Jpn. J. Clin. Oncol., 2015, 45(12), 1107-1115.
[http://dx.doi.org/10.1093/jjco/hyv150 ] [PMID: 26491203]
[68]
Qiu, W.; Lu, H.; Qi, Y.; Wang, X. Dietary fat intake and ovarian cancer risk: a meta-analysis of epidemiological studies. Oncotarget, 2016, 7(24), 37390-37406.
[http://dx.doi.org/10.18632/oncotarget.8940 ] [PMID: 27119509]
[69]
Licaj, I.; Jacobsen, B.K.; Selmer, R.M.; Maskarinec, G.; Weiderpass, E.; Gram, I.T. Smoking and risk of ovarian cancer by histological subtypes: an analysis among 300 000 Norwegian women. Br. J. Cancer, 2017, 116(2), 270-276.
[http://dx.doi.org/10.1038/bjc.2016.418 ] [PMID: 27959888]
[70]
Faber, M.T.; Kjær, S.K.; Dehlendorff, C.; Chang-Claude, J.; Andersen, K.K.; Høgdall, E.; Webb, P.M.; Jordan, S.J.; Rossing, M.A.; Doherty, J.A.; Lurie, G.; Thompson, P.J.; Carney, M.E.; Goodman, M.T.; Ness, R.B.; Modugno, F.; Edwards, R.P.; Bunker, C.H.; Goode, E.L.; Fridley, B.L.; Vierkant, R.A.; Larson, M.C.; Schildkraut, J.; Cramer, D.W.; Terry, K.L.; Vitonis, A.F.; Bandera, E.V.; Olson, S.H.; King, M.; Chandran, U.; Kiemeney, L.A.; Massuger, L.F.; van Altena, A.M.; Vermeulen, S.H.; Brinton, L.; Wentzensen, N.; Lissowska, J.; Yang, H.P.; Moysich, K.B.; Odunsi, K.; Kasza, K.; Odunsi-Akanji, O.; Song, H.; Pharaoh, P.; Shah, M.; Whittemore, A.S.; McGuire, V.; Sieh, W.; Sutphen, R.; Menon, U.; Gayther, S.A.; Ramus, S.J.; Gentry-Maharaj, A.; Pearce, C.L.; Wu, A.H.; Pike, M.C.; Risch, H.A.; Jensen, A. Australian cancer study (ovarian cancer); Australian ovarian cancer study group; Ovarian cancer association consortium. Cigarette smoking and risk of ovarian cancer: a pooled analysis of 21 case-control studies. Cancer Causes Control, 2013, 24(5), 989-1004.
[http://dx.doi.org/10.1007/s10552-013-0174-4 ] [PMID: 23456270]
[71]
Coan, M.; Rampioni Vinciguerra, G.L.; Cesaratto, L.; Gardenal, E.; Bianchet, R.; Dassi, E.; Vecchione, A.; Baldassarre, G.; Spizzo, R.; Nicoloso, M.S. Exploring the role of fallopian ciliated cells in the pathogenesis of high-grade se-rous ovarian cancer. Int. J. Mol. Sci., 2018, 19(9), 2512-2534.
[http://dx.doi.org/10.3390/ijms19092512 ] [PMID: 30149579]
[72]
Vercellini, P.; Crosignani, P.; Somigliana, E.; Viganò, P.; Buggio, L.; Bolis, G.; Fedele, L. The ‘incessant menstruation’ hypothesis: a mechanistic ovarian cancer model with implications for prevention. Hum. Reprod., 2011, 26(9), 2262-2273.
[http://dx.doi.org/10.1093/humrep/der211 ] [PMID: 21724568]
[73]
Toyokuni, S. Role of iron in carcinogenesis: cancer as a ferrotoxic disease. Cancer Sci., 2009, 100(1), 9-16.
[http://dx.doi.org/10.1111/j.1349-7006.2008.01001.x ] [PMID: 19018762]
[74]
Cohen, S.; Mehrabi, S.; Yao, X.; Millingen, S.; Aikhionbare, F.O. Reactive oxygen species and serous epithelial ovarian adenocarcinoma. Cancer Res. J. (N. Y. N. Y.), 2016, 4(6), 106-114.
[http://dx.doi.org/10.11648/j.crj.20160406.13 ] [PMID: 28503633]
[75]
Wang, Y.; Ma, J.; Shen, H.; Wang, C.; Sun, Y.; Howell, S.B.; Lin, X. Reactive oxygen species promote ovarian cancer progression via the HIF-1α/LOX/E-cadherin pathway. Oncol. Rep., 2014, 32(5), 2150-2158.
[http://dx.doi.org/10.3892/or.2014.3448 ] [PMID: 25174950]
[76]
Zheng, G.; Yu, H.; Kanerva, A.; Försti, A.; Sundquist, K.; Hemminki, K. Familial ovarian cancer clusters with other cancers. Sci. Rep., 2018, 8(1), 11561.
[http://dx.doi.org/10.1038/s41598-018-29888-4 ] [PMID: 30069056]
[77]
Toss, A.; Tomasello, C.; Razzaboni, E.; Contu, G.; Grandi, G.; Cagnacci, A.; Schilder, R.J.; Cortesi, L. Hereditary ovarian cancer: not only BRCA 1 and 2 genes. BioMed Res. Int., 2015, 2015(341723):341723.
[http://dx.doi.org/10.1155/2015/341723 ] [PMID: 26075229]
[78]
Nakonechny, Q.B.; Gilks, C.B. Ovarian cancer in hereditary cancer susceptibility syndromes. Surg. Pathol. Clin., 2016, 9(2), 189-199.
[http://dx.doi.org/10.1016/j.path.2016.01.003 ] [PMID: 27241103]
[79]
Edge, S.B.; Compton, C.C. , 2010.
[80]
www.cancerstaging.orgwww.cancer.org/cancer/ovarian-cancer/detection-diagnosis-staging/staging.html
[81]
Reade, C.J.; Riva, J.J.; Busse, J.W.; Goldsmith, C.H.; Elit, L. Risks and benefits of screening asymptomatic women for ovarian cancer: a systematic review and meta-analysis. Gynecol. Oncol., 2013, 130(3), 674-681.
[http://dx.doi.org/10.1016/j.ygyno.2013.06.029 ] [PMID: 23822892]
[82]
Carvalho, J., Jr; Formighieri, B.; Filippi, S.; Rossini, L. Location of recurrent asymptomatic ovarian cancer through endoscopic ultrasound. Endosc. Ultrasound, 2015, 4(1), 63-65.
[http://dx.doi.org/10.4103/2303-9027.151353 ] [PMID: 25789287]
[83]
Doubeni, C.A.; Doubeni, A.R.; Myers, A.E. Diagnosis and management of ovarian cancer. Am. Fam. Physician, 2016, 93(11), 937-944.
[PMID: 27281838]
[84]
Kujawa, K.A.; Lisowska, K.M. Ovarian cancer - from biology to clinic. Postepy Hig. Med. Dosw., 2015, 69, 1275-1290.
[http://dx.doi.org/10.5604/17322693.1184451]
[85]
Yancik, R. Ovarian cancer. Age contrasts in incidence, histology, disease stage at diagnosis, and mortality. Cancer, 1993, 71(Suppl. 2), 517-523.
[http://dx.doi.org/10.1002/cncr.2820710205 ] [PMID: 8420671]
[86]
Disease-oriented reasearch. Gynecological Tumors c/o Istituto Europeo di Oncologia, 2012.
[87]
Kitajima, K.; Murakami, K.; Yamasaki, E.; Kaji, Y.; Fukasawa, I.; Inaba, N.; Sugimura, K. Diagnostic accuracy of integrated FDG-PET/contrast-enhanced CT in staging ovarian cancer: comparison with enhanced CT. Eur. J. Nucl. Med. Mol. Imaging, 2008, 35(10), 1912-1920.
[http://dx.doi.org/10.1007/s00259-008-0890-2 ] [PMID: 18682935]
[88]
Visintin, I.; Feng, Z.; Longton, G.; Ward, D.C.; Alvero, A.B.; Lai, Y.; Tenthorey, J.; Leiser, A.; Flores-Saaib, R.; Yu, H.; Azori, M.; Rutherford, T.; Schwartz, P.E.; Mor, G. Diagnostic markers for early detection of ovarian cancer. Clin. Cancer Res., 2008, 14(4), 1065-1072.
[http://dx.doi.org/10.1158/1078-0432.CCR-07-1569 ] [PMID: 18258665]
[89]
Buchen, L. Cancer: missing the mark. Nature, 2011, 471(7339), 428-432.
[http://dx.doi.org/10.1038/471428a ] [PMID: 21430749]
[90]
Petricoin, E.F.; Ardekani, A.M.; Hitt, B.A.; Levine, P.J.; Fusaro, V.A.; Steinberg, S.M.; Mills, G.B.; Simone, C.; Fishman, D.A.; Kohn, E.C.; Liotta, L.A. Use of proteomic patterns in serum to identify ovarian cancer. Lancet, 2002, 359(9306), 572-577.
[http://dx.doi.org/10.1016/S0140-6736(02)07746-2 ] [PMID: 11867112]
[91]
Fong, T. Correlogic Files for. Chapter 11; Bankruptcy Protection Genomeweb, 2010.
[92]
Yip, P.; Chen, T.H.; Seshaiah, P.; Stephen, L.L.; Michael-Ballard, K.L.; Mapes, J.P.; Mansfield, B.C.; Bertenshaw, G.P. Comprehensive serum profiling for the discovery of epithelial ovarian cancer biomarkers. PLoS One, 2011, 6(12):e29533.
[http://dx.doi.org/10.1371/journal.pone.0029533 ] [PMID: 22216306]
[93]
Fung, E.T. A recipe for proteomics diagnostic test development: the OVA1 test, from biomarker discovery to FDA clearance. Clin. Chem., 2010, 56(2), 327-329.
[http://dx.doi.org/10.1373/clinchem.2009.140855 ] [PMID: 20110452]
[94]
Gu, P.; Pan, L.L.; Wu, S.Q.; Sun, L.; Huang, G. CA 125, PET alone, PET-CT, CT and MRI in diagnosing recurrent ovarian carcinoma: a systematic review and meta-analysis. Eur. J. Radiol., 2009, 71(1), 164-174.
[http://dx.doi.org/10.1016/j.ejrad.2008.02.019 ] [PMID: 18378417]
[95]
Yuan, Y.; Gu, Z.X.; Tao, X.F.; Liu, S.Y. Computer tomography, magnetic resonance imaging, and positron emission tomography or positron emission tomography/computer tomography for detection of metastatic lymph nodes in patients with ovarian cancer: a meta-analysis. Eur. J. Radiol., 2012, 81(5), 1002-1006.
[http://dx.doi.org/10.1016/j.ejrad.2011.01.112 ] [PMID: 21349672]
[96]
Gupta, R.A.; Tejada, L.V.; Tong, B.J.; Das, S.K.; Morrow, J.D.; Dey, S.K.; DuBois, R.N. Cyclooxygenase-1 is overexpressed and promotes angiogenic growth factor production in ovarian cancer. Cancer Res., 2003, 63(5), 906-911.
[PMID: 12615701]
[97]
Zeng, X.; Yi, S. Cyclooxygenase inhibitors in epithelial ovarian cancer treatment. Int. J. Gynecol. Cancer, 2018, 28(6), 1085-1089.
[http://dx.doi.org/10.1097/IGC.0000000000001269 ] [PMID: 29727350]
[98]
Perrone, M.G.; Malerba, P.; Uddin, J.; Vitale, P.; Panella, A.; Crews, B.C.; Daniel, C.K.; Ghebreselasie, K.; Nickels, M.; Tantawy, M.N.; Manning, H.C.; Marnett, L.J.; Scilimati, A. PET radiotracer [18F]-P6 selectively targeting COX-1 as a novel biomarker in ovarian cancer: preliminary investigation. Eur. J. Med. Chem., 2014, 80, 562-568.
[http://dx.doi.org/10.1016/j.ejmech.2014.04.074 ] [PMID: 24832612]
[99]
Karimi-Zarchi, M.; Mojaver, S.P.; Rouhi, M.; Hekmatimoghaddam, S.H.; Moghaddam, R.N.; Yazdian-Anari, P.; Teimoori, S. Diagnostic value of the risk of malignancy index (RMI) for detection of pelvic malignancies compared with pathology. Electron. Physician, 2015, 7(7), 1505-1510.
[http://dx.doi.org/10.19082/1505 ] [PMID: 26767105]
[100]
Buhling, K.J.; Lezon, S.; Eulenburg, C.; Schmalfeldt, B. The role of transvaginal ultrasonography for detecting ovarian cancer in an asymptomatic screening population: a systematic review. Arch. Gynecol. Obstet., 2017, 295(5), 1259-1268.
[http://dx.doi.org/10.1007/s00404-017-4346-4 ] [PMID: 28357559]
[101]
Fleming, N.D.; Cass, I.; Walsh, C.S.; Karlan, B.Y.; Li, A.J. CA125 surveillance increases optimal resectability at secondary cytoreductive surgery for recurrent epithelial ovarian cancer. Gynecol. Oncol., 2011, 121(2), 249-252.
[http://dx.doi.org/10.1016/j.ygyno.2011.01.014 ] [PMID: 21300398]
[102]
Wang, F.; Ye, Y.; Xu, X.; Zhou, X.; Wang, J.; Chen, X. CA-125-indicated asymptomatic relapse confers survival benefit to ovarian cancer patients who underwent secondary cytoreduction surgery. J. Ovarian Res., 2013, 6(1), 14.
[http://dx.doi.org/10.1186/1757-2215-6-14 ] [PMID: 23402322]
[103]
Li, J.; Dowdy, S.; Tipton, T.; Podratz, K.; Lu, W.G.; Xie, X.; Jiang, S.W. HE4 as a biomarker for ovarian and endometrial cancer management. Expert Rev. Mol. Diagn., 2009, 9(6), 555-566.
[http://dx.doi.org/10.1586/erm.09.39 ] [PMID: 19732003]
[104]
Van Gorp, T.; Cadron, I.; Despierre, E.; Daemen, A.; Leunen, K.; Amant, F.; Timmerman, D.; De Moor, B.; Vergote, I. HE4 and CA125 as a diagnostic test in ovarian cancer: prospective validation of the risk of ovarian malignancy algorithm. Br. J. Cancer, 2011, 104(5), 863-870.
[http://dx.doi.org/10.1038/sj.bjc.6606092 ] [PMID: 21304524]
[105]
Meyer, T.; Rustin, G.J. Role of tumour markers in monitoring epithelial ovarian cancer. Br. J. Cancer, 2000, 82(9), 1535-1538.
[PMID: 10789720]
[106]
Corzo, C.; Iniesta, M.D.; Patrono, M.G.; Lu, K.H.; Ramirez, P.T. Role of Fallopian Tubes in the development of ovarian cancer. J. Minim. Invasive Gynecol., 2017, 24(2), 230-234.
[http://dx.doi.org/10.1016/j.jmig.2016.12.007 ] [PMID: 28007588]
[107]
Bereka, J.S.; Crum, C.; Friedlander, M. FIGO Cancer Report 2012: cancer of the ovary, fallopian tube, and peritoneum. Int. J. Gynaecol. Obstet., 2012, 119, 118-129.
[http://dx.doi.org/10.1016/S0020-7292(12)60025-3]
[108]
Singh, N.; Gilks, C.B.; Wilkinson, N.; McCluggage, W.G. Assignment of primary site in high-grade serous tubal, ovarian and peritoneal carcinoma: a proposal. Histopathology, 2014, 65(2), 149-154.
[http://dx.doi.org/10.1111/his.12419 ] [PMID: 24660659]
[109]
Wilkinson, N.; McCluggage, W.M. Standards and datasets for reporting cancers: datasets for the histopathological reporting of neoplasms of the ovaries and fallopian tubes and primary carcinomas of the peritoneum, 3rd ed; The Royal College of Pathologists: UK, 2010.
[110]
WHO Classification of Tumours. Tumours of the breast and female genital organs.Tumours of the ovary and peritoneum. Lyons; IARC Press, 2003.
[111]
Moss, E.L.; Evans, T.; Pearmain, P.; Askew, S.; Singh, K.; Chan, K.K.; Ganesan, R.; Hirschowitz, L. Should all cases of high-grade serous ovarian, tubal, and primary peritoneal car-cinomas be reclassified as tubo-ovarian Serous Carcinoma? Int. J. Gynecol. Cancer, 2015, 25(7), 1201-1207.
[http://dx.doi.org/10.1097/IGC.0000000000000477 ] [PMID: 26035124]
[112]
Gan, C.; Chenoy, R.; Chandrasekaran, D.; Brockbank, E.; Hollingworth, A.; Vimplis, S.; Lawrence, A.C.; Jeyarajah, A.R.; Oram, D.; Deo, N.; Saravanamuthu, J.; Lam, S.S.; Faruqi, A.; Singh, N.; Manchanda, R. Persistence of fimbrial tissue on the ovarian surface after salpingectomy. Am. J. Obstet. Gynecol., 2017, 217(4), 425.e1-425.e16.
[http://dx.doi.org/10.1016/j.ajog.2017.06.004 ] [PMID: 28610900]
[113]
Vitale, P.; Panella, A.; Scilimati, A.; Perrone, M.G. COX-1 inhibitors: beyond structure toward therapy. Med. Res. Rev., 2016, 36(4), 641-671.
[http://dx.doi.org/10.1002/med.21389 ] [PMID: 27111555]
[114]
Vitale, P.; Scilimati, A.; Perrone, M.G. Update on SAR studies toward new COX-1 selective inhibitors. Curr. Med. Chem., 2015, 22(37), 4271-4292.
[http://dx.doi.org/10.2174/0929867322666151029104717 ] [PMID: 26511468]
[115]
Vitale, P.; Perrone, M.G.; Malerba, P.; Lavecchia, A.; Scilimati, A. Selective COX-1 inhibition as a target of theranostic novel diarylisoxazoles. Eur. J. Med. Chem., 2014, 74, 606-618.
[http://dx.doi.org/10.1016/j.ejmech.2013.12.023 ] [PMID: 24531199]
[116]
Perrone, M.G.; Vitale, P.; Ferorelli, S.; Boccarelli, A.; Coluccia, M.; Pannunzio, A.; Campanella, F.; Di Mauro, G.; Bonaccorso, C.; Fortuna, C.G.; Scilimati, A. Effect of mofezolac-galactose distance in conjugates targeting cyclooxygenase (COX)-1 and CNS GLUT-1 carrier. Eur. J. Med. Chem., 2017, 141, 404-416.
[http://dx.doi.org/10.1016/j.ejmech.2017.09.066 ] [PMID: 29032033]
[117]
Cingolani, G.; Panella, A.; Perrone, M.G.; Vitale, P.; Di Mauro, G.; Fortuna, C.G.; Armen, R.S.; Ferorelli, S.; Smith, W.L.; Scilimati, A. Structural basis for selective inhibition of Cyclooxygenase(COX-1) by diarylisoxazoles derivatives. Eur. J. Med. Chem., 2017, 138, 661-668.
[http://dx.doi.org/10.1016/j.ejmech.2017.06.045 ] [PMID: 28710965]
[118]
Perrone, M.G.; Lofrumento, D.D.; Vitale, P.; De Nuccio, F.; La Pesa, V.; Panella, A.; Calvello, R.; Cianciulli, A.; Panaro, M.A.; Scilimati, A. Selective cyclooxygenase-1 inhibition by p6 and gastrotoxicity: preliminary investigation. Pharmacology, 2015, 95(1-2), 22-28.
[http://dx.doi.org/10.1159/000369826 ] [PMID: 25591798]
[119]
Perrone, M.G.; Vitale, P.; Panella, A.; Ferorelli, S.; Contino, M.; Lavecchia, A.; Scilimati, A. Isoxazole-based scaffold inhibitors targeting cyclooxygenases (COXs). ChemMedChem, 2016, 11(11), 1172-1187.
[http://dx.doi.org/10.1002/cmdc.201500439 ] [PMID: 27136372]
[120]
Perrone, M.G.; Vitale, P.; Panella, A.; Fortuna, C.G.; Scilimati, A. General role of the amino and methylsulfamoyl groups in selective cyclooxygenase(COX)-1 inhibition by 1,4-diaryl-1,2,3-triazoles and validation of a predictive pharmacometric PLS model. Eur. J. Med. Chem., 2015, 94, 252-264.
[http://dx.doi.org/10.1016/j.ejmech.2015.02.049 ] [PMID: 25768707]
[121]
Yildrim, Y. Cytoreductive surgery in Gynecologic Oncology: A Multidisciplinary Approach; Published by Transworld Re-search NetworkEditor, 2010.
[122]
Castellani, F.; Nganga, E.C.; Dumas, L.; Banerjee, S.; Rock-all, A.G. Imaging in the preoperative staging of ovarian cancer. Abdom. Radiol. (N.Y.), 2018, 1-12.
[123]
Nayak, A.P.; Kapur, A.; Barroilhet, L.; Patankar, M.S. Oxidative Phosphorylation: a target for novel therapeutic strate-gies against ovarian cancer. Cancers (Basel), 2018, 10(9)E337
[http://dx.doi.org/10.3390/cancers10090337 ] [PMID: 30231564]
[124]
Grisham, R.N.; Iyer, G. Low-grade serous ovarian cancer: current treatment paradigms and future directions. Curr. Treat. Options Oncol., 2018, 19(11), 54.
[http://dx.doi.org/10.1007/s11864-018-0571-8 ] [PMID: 30225651]
[125]
Cortez, A.J.; Tudrej, P.; Kujawa, K.A.; Lisowska, K.M. Advances in ovarian cancer therapy. Cancer Chemother. Pharmacol., 2018, 81(1), 17-38.
[http://dx.doi.org/10.1007/s00280-017-3501-8 ] [PMID: 29249039]
[126]
Ledermann, J.A.; Raja, F.A.; Fotopoulou, C.; Gonzalez-Martin, A.; Colombo, N.; Sessa, C. ESMO guidelines working group. Newly diagnosed and relapsed epithelial ovarian carcinoma: ESMO clinical practice guidelines for diagnosis, treatment and follow-up. Ann. Oncol., 2013, 24(Suppl. 6), vi24-vi32.
[http://dx.doi.org/10.1093/annonc/mdt333 ] [PMID: 24078660]
[127]
Kiselev, V.I.; Ashrafyan, L.A.; Muyzhnek, E.L.; Gerfanova, E.V.; Antonova, I.B.; Aleshikova, O.I.; Sarkar, F.H. A new promising way of maintenance therapy in advanced ovarian cancer: a comparative clinical study. BMC Cancer, 2018, 18(1), 904-930.
[http://dx.doi.org/10.1186/s12885-018-4792-9 ] [PMID: 30236079]
[128]
Jessmon, P.; Boulanger, T.; Zhou, W.; Patwardhan, P. Epidemiology and treatment patterns of epithelial ovarian cancer. Expert Rev. Anticancer Ther., 2017, 17(5), 427-437.
[http://dx.doi.org/10.1080/14737140.2017.1299575 ] [PMID: 28277806]
[129]
Schmid, B.C.; Oehler, M.K. New perspectives in ovarian cancer treatment. Maturitas, 2014, 77(2), 128-136.
[http://dx.doi.org/10.1016/j.maturitas.2013.11.009 ] [PMID: 24380827]
[130]
Ferrara, N.; Hillan, K.J.; Novotny, W. Bevacizumab (Avastin), a humanized anti-VEGF monoclonal antibody for cancer therapy. Biochem. Biophys. Res. Commun., 2005, 333(2), 328-335.
[http://dx.doi.org/10.1016/j.bbrc.2005.05.132 ] [PMID: 15961063]
[131]
Eichbaum, M.; Mayer, C.; Eickhoff, R.; Bischofs, E.; Gebauer, G.; Fehm, T.; Lenz, F.; Fricke, H-C.; Solomayer, E.; Fersis, N.; Schmidt, M.; Wallwiener, M.; Schneeweiss, A.; Sohn, C. The PACOVAR-trial: a phase I/II study of pazopanib (GW786034) and cyclophosphamide in patients with platinum-resistant recurrent, pre-treated ovarian cancer. BMC Cancer, 2011, 11, 453.
[http://dx.doi.org/10.1186/1471-2407-11-453 ] [PMID: 22014006]
[132]
duBois, A.; Floquet, A.; Kim, J. A Phase III, randomized, double-blind trial of pazopanib versus placebo in women who have not progressed after first-line chemotherapy for advanced epithelial ovarian, fallopian tube, or primary peritoneal cancer (AEOC): results of an international intergroup trial (AGO-OVAR 16). Am. Soc. Clin. Oncol., 2017, 31(18).
[http://dx.doi.org/10.1200/jco.2013.31.18_suppl.lba5503]
[133]
Efficacy, GSK Efficacy and safety of pazopanib monotherapy after first-line chemotherapy in ovarian, fallopian tube, or primary peritoneal cancer in Asian women. NCT00866697, 2018.
[134]
Boehringer Ingelheim. LUME-Ovar-1, LUME-ovar 1: Nintedanib (BIBF 1120) or placebo in combination with paclitaxel and carboplatin in first line treatment of ovarian cancer. NCT01015118, 2017.
[135]
ICON6. An RCT of concurrent and maintenance cediranib in women with platinum-sensitive relapsed ovarian cancer (ICON6). NCT00532194 2015.
[136]
Ledermann, J.A.; Perren, T.; Raja, F.A.; Embleton, A.C.; Rustin, G.J.S.; Jayson, G.; Kaye, S.B.; Swart, A.; Vaughan, M.; Hirte, H. Randomised double-blind phase III trial of Cediranib (AZD 2171) in relapsed platinum sensitive ovarian cancer: results of the ICON6 trial. European Cancer Congress, 2013.
[137]
Kamen, B. Folate and antifolate pharmacology. Semin. Oncol, 1997, 24(5), S18-30-S18-39
[PMID: 9420019]
[138]
Amstutz, U.; Froehlich, T.K.; Largiadèr, C.R. Dihydropyrimidine dehydrogenase gene as a major predictor of severe 5-fluorouracil toxicity. Pharmacogenomics, 2011, 12(9), 1321-1336.
[http://dx.doi.org/10.2217/pgs.11.72 ] [PMID: 21919607]
[139]
Kałużna, E.; Strauss, E.; Zając-Spychała, O.; Gowin, E.; Świątek-Kościelna, B.; Nowak, J.; Fichna, M.; Mańkowski, P.; Januszkiewicz-Lewandowska, D. Functional variants of gene encoding folate metabolizing enzyme and methotrexate-related toxicity in children with acute lymphoblastic leukemia. Eur. J. Pharmacol., 2015, 769, 93-99.
[http://dx.doi.org/10.1016/j.ejphar.2015.10.058 ] [PMID: 26528799]
[140]
Rajagopalan, P.T.; Zhang, Z.; McCourt, L.; Dwyer, M.; Benkovic, S.J.; Hammes, G.G. Interaction of dihydrofolate reductase with methotrexate: ensemble and single-molecule kinetics. Proc. Natl. Acad. Sci. USA, 2002, 99(21), 13481-13486.
[http://dx.doi.org/10.1073/pnas.172501499 ] [PMID: 12359872]
[141]
Longley, D.B.; Harkin, D.P.; Johnston, P.G. 5-fluorouracil: mechanisms of action and clinical strategies. Nat. Rev. Cancer, 2003, 3(5), 330-338.
[http://dx.doi.org/10.1038/nrc1074 ] [PMID: 12724731]
[142]
Vergote, I.; Calvert, H.; Kania, M.; Kaiser, C.; Zimmermann, A.H.; Sehouli, J. A randomised, double-blind, phase II study of two doses of pemetrexed in the treatment of platinum-resistant, epithelial ovarian or primary peritoneal cancer. Eur. J. Cancer, 2009, 45(8), 1415-1423.
[http://dx.doi.org/10.1016/j.ejca.2008.12.013 ] [PMID: 19168349]
[143]
Hagemann, A.R.; Novetsky, A.P.; Zighelboim, I.; Gao, F.; Massad, L.S.; Thaker, P.H.; Powell, M.A.; Mutch, D.G.; Wright, J.D. Phase II study of bevacizumab and pemetrexed for recurrent or persistent epithelial ovarian, fallopian tube or primary peritoneal cancer. Gynecol. Oncol., 2013, 131(3), 535-540.
[http://dx.doi.org/10.1016/j.ygyno.2013.09.032 ] [PMID: 24096113]
[144]
Toffoli, G.; Cernigoi, C.; Russo, A.; Gallo, A.; Bagnoli, M.; Boiocchi, M. Overexpression of folate binding protein in ovarian cancers. Int. J. Cancer, 1997, 74(2), 193-198.
[http://dx.doi.org/10.1002/(SICI)1097-0215(19970422)74:2<193:AID-IJC10>3.0.CO;2-F ] [PMID: 9133455]
[145]
Crane, L.M.; Arts, H.J.; van Oosten, M.; Low, P.S.; van der Zee, A.G.; van Dam, G.M.; Bart, J. The effect of chemotherapy on expression of folate receptor-alpha in ovarian cancer. Cell Oncol. (Dordr.), 2012, 35(1), 9-18.
[http://dx.doi.org/10.1007/s13402-011-0052-6 ] [PMID: 21647742]
[146]
Leamon, C.P.; Reddy, J.A. Folate-targeted chemotherapy. Adv. Drug Deliv. Rev., 2004, 56(8), 1127-1141.
[http://dx.doi.org/10.1016/j.addr.2004.01.008 ] [PMID: 15094211]
[147]
Torrisi, R.; Rota, S.; Losurdo, A.; Zuradelli, M.; Masci, G.; Santoro, A. Aromatase inhibitors in premenopause: Great expectations fulfilled? Crit. Rev. Oncol. Hematol., 2016, 107, 82-89.
[148]
Vlahov, I.R.; Santhapuram, H.K.; Kleindl, P.J.; Howard, S.J.; Stanford, K.M.; Leamon, C.P. Design and regioselective synthesis of a new generation of targeted chemotherapeutics. Part 1: EC145, a folic acid conjugate of desacetylvinblastine monohydrazide. Bioorg. Med. Chem. Lett., 2006, 16(19), 5093-5096.
[http://dx.doi.org/10.1016/j.bmcl.2006.07.030 ] [PMID: 16870437]
[149]
Scilimati, A.; Ferorelli, S.; Iaselli, M.C.; Miciaccia, M.; Pati, M.L.; Fortuna, C.G.; Aleem, A.M.; Marnett, L.J.; Perrone, M.G. Targeting COX-1 by mofezolac-based fluorescent probes for ovarian cancer detection. Eur. J. Med. Chem., 2019, 179, 16-25.
[http://dx.doi.org/10.1016/j.ejmech.2019.06.039 ] [PMID: 31229884]
[150]
Slamon, D.J.; Clark, G.M.; Wong, S.G.; Levin, W.J.; Ullrich, A.; McGuire, W.L. Human breast cancer: correlation of relapse and survival with amplification of the HER-2/neu oncogene. Science, 1987, 235(4785), 177-182.
[http://dx.doi.org/10.1126/science.3798106 ] [PMID: 3798106]
[151]
Farley, J.; Fuchiuji, S.; Darcy, K.M.; Tian, C.; Hoskins, W.J.; McGuire, W.P.; Hanjani, P.; Warshal, D.; Greer, B.E.; Belinson, J.; Birrer, M.J. Associations between ERBB2 amplification and progression-free survival and overall survival in advanced stage, suboptimally-resected epithelial ovarian cancers: a gynecologic oncology group study. Gynecol. Oncol., 2009, 113(3), 341-347.
[http://dx.doi.org/10.1016/j.ygyno.2009.02.009 ] [PMID: 19272639]
[152]
Balduzzi, S.; Mantarro, S.; Guarneri, V.; Tagliabue, L.; Pistotti, V.; Moja, L.; D’Amico, R. Trastuzumab-containing regimens for metastatic breast cancer. Cochrane Database Syst. Rev., 2014, 18(6)CD006242
[PMID: 24919460]
[153]
Moya-Horno, I.; Cortés, J. The expanding role of pertuzumab in the treatment of HER2-positive breast cancer. Breast Cancer (Dove Med. Press), 2015, 7, 125-132.
[PMID: 26056489]
[154]
Bookman, M.A.; Darcy, K.M.; Clarke-Pearson, D.; Boothby, R.A.; Horowitz, I.R. Evaluation of monoclonal humanized anti-HER2 antibody, trastuzumab, in patients with recurrent or refractory ovarian or primary peritoneal carcinoma with overexpression of HER2: a phase II trial of the Gynecologic Oncology Group. J. Clin. Oncol., 2003, 21(2), 283-290.
[http://dx.doi.org/10.1200/JCO.2003.10.104 ] [PMID: 12525520]
[155]
Makhija, S.; Amler, L.C.; Glenn, D.; Ueland, F.R.; Gold, M.A.; Dizon, D.S.; Paton, V.; Lin, C.Y.; Januario, T.; Ng, K.; Strauss, A.; Kelsey, S.; Sliwkowski, M.X.; Matulonis, U. Clinical activity of gemcitabine plus pertuzumab in platinum-resistant ovarian cancer, fallopian tube cancer, or primary peritoneal cancer. J. Clin. Oncol., 2010, 28(7), 1215-1223.
[http://dx.doi.org/10.1200/JCO.2009.22.3354 ] [PMID: 19901115]
[156]
Simpkins, F.; Hevia-Paez, P.; Sun, J.; Ullmer, W.; Gilbert, C.A.; da Silva, T.; Pedram, A.; Levin, E.R.; Reis, I.M.; Rabinovich, B.; Azzam, D.; Xu, X.X.; Ince, T.A.; Yang, J.Y.; Verhaak, R.G.; Lu, Y.; Mills, G.B.; Slingerland, J.M. Src Inhibition with saracatinib reverses fulvestrant resistance in ER-positive ovarian cancer models in vitro and in vivo. Clin. Cancer Res., 2012, 18(21), 5911-5923.
[http://dx.doi.org/10.1158/1078-0432.CCR-12-1257 ] [PMID: 22896656]
[157]
Simpkins, F.; Garcia-Soto, A.; Slingerland, J. New insights on the role of hormonal therapy in ovarian cancer. Steroids, 2013, 78(6), 530-537.
[http://dx.doi.org/10.1016/j.steroids.2013.01.008 ] [PMID: 23402742]
[158]
Argenta, P.A.; Thomas, S.G.; Judson, P.L.; Downs, L.S., Jr; Geller, M.A.; Carson, L.F.; Jonson, A.L.; Ghebre, R. A phase II study of fulvestrant in the treatment of multiply-recurrent epithelial ovarian cancer. Gynecol. Oncol., 2009, 113(2), 205-209.
[http://dx.doi.org/10.1016/j.ygyno.2009.01.012 ] [PMID: 19239974]
[159]
Miller, W.R.; Jackson, J. The therapeutic potential of aromatase inhibitors. Expert Opin. Investig. Drugs, 2003, 12(3), 337-351.
[http://dx.doi.org/10.1517/13543784.12.3.337 ] [PMID: 12605559]
[160]
del Carmen, M.G.; Fuller, A.F.; Matulonis, U.; Horick, N.K.; Goodman, A.; Duska, L.R.; Penson, R.; Campos, S.; Roche, M.; Seiden, M.V. Phase II trial of anastrozole in women with asymptomatic müllerian cancer. Gynecol. Oncol., 2003, 91(3), 596-602.
[http://dx.doi.org/10.1016/j.ygyno.2003.08.021 ] [PMID: 14675683]
[161]
Smyth, J.F.; Gourley, C.; Walker, G.; MacKean, M.J.; Stevenson, A.; Williams, A.R.; Nafussi, A.A.; Rye, T.; Rye, R.; Stewart, M.; McCurdy, J.; Mano, M.; Reed, N.; McMahon, T.; Vasey, P.; Gabra, H.; Langdon, S.P. Antiestrogen therapy is active in selected ovarian cancer cases: the use of letrozole in estrogen receptor-positive patients. Clin. Cancer Res., 2007, 13(12), 3617-3622.
[http://dx.doi.org/10.1158/1078-0432.CCR-06-2878 ] [PMID: 17575226]
[162]
Lombardi, P. Exemestane, a new steroidal aromatase inhibitor of clinical relevance. Biochim. Biophys. Acta, 2002, 1587(2-3), 326-337.
[http://dx.doi.org/10.1016/S0925-4439(02)00096-0 ] [PMID: 12084475]
[163]
Verma, S.; Alhayki, M.; Le, T.; Balnes, K.; Rambout, L.; Hopkins, L.; Fung, M.F.K. Phase II study of exemestane (E) in refractory ovarian cancer (ROC). J. Clin. Oncol., 2006, •••, 24.
[http://dx.doi.org/10.1200/jco.2006.24.18_suppl.5026]
[164]
Ashworth, A. A synthetic lethal therapeutic approach: poly(ADP) ribose polymerase inhibitors for the treatment of cancers deficient in DNA double-strand break repair. J. Clin. Oncol., 2008, 26(22), 3785-3790.
[http://dx.doi.org/10.1200/JCO.2008.16.0812 ] [PMID: 18591545]
[165]
Morales, J.; Li, L.; Fattah, F.J.; Dong, Y.; Bey, E.A.; Patel, M.; Gao, J.; Boothman, D.A. Review of poly (ADP-ribose) polymerase (PARP) mechanisms of action and rationale for targeting in cancer and other diseases. Crit. Rev. Eukaryot. Gene Expr., 2014, 24(1), 15-28.
[http://dx.doi.org/10.1615/CritRevEukaryotGeneExpr.2013006875 ] [PMID: 24579667]
[166]
Farmer, H.; McCabe, N.; Lord, C.J.; Tutt, A.N.; Johnson, D.A.; Richardson, T.B.; Santarosa, M.; Dillon, K.J.; Hickson, I.; Knights, C.; Martin, N.M.; Jackson, S.P.; Smith, G.C.; Ashworth, A. Targeting the DNA repair defect in BRCA mutant cells as a therapeutic strategy. Nature, 2005, 434(7035), 917-921.
[http://dx.doi.org/10.1038/nature03445 ] [PMID: 15829967]
[167]
Bryant, H.E.; Schultz, N.; Thomas, H.D.; Parker, K.M.; Flower, D.; Lopez, E.; Kyle, S.; Meuth, M.; Curtin, N.J.; Helleday, T. Specific killing of BRCA2-deficient tumours with inhibitors of poly(ADP-ribose) polymerase. Nature, 2005, 434(7035), 913-917.
[http://dx.doi.org/10.1038/nature03443 ] [PMID: 15829966]
[168]
Audeh, M.W.; Carmichael, J.; Penson, R.T.; Friedlander, M.; Powell, B.; Bell-McGuinn, K.M.; Scott, C.; Weitzel, J.N.; Oaknin, A.; Loman, N.; Lu, K.; Schmutzler, R.K.; Matulonis, U.; Wickens, M.; Tutt, A. Oral poly(ADP-ribose) polymerase inhibitor olaparib in patients with BRCA1 or BRCA2 mutations and recurrent ovarian cancer: a proof-of-concept trial. Lancet, 2010, 376(9737), 245-251.
[http://dx.doi.org/10.1016/S0140-6736(10)60893-8 ] [PMID: 20609468]
[169]
Gelmon, K.A.; Tischkowitz, M.; Mackay, H.; Swenerton, K.; Robidoux, A.; Tonkin, K.; Hirte, H.; Huntsman, D.; Clemons, M.; Gilks, B.; Yerushalmi, R.; Macpherson, E.; Carmichael, J.; Oza, A. Olaparib in patients with recurrent high-grade serous or poorly differentiated ovarian carcinoma or triple-negative breast cancer: a phase 2, multicentre, open-label, non-randomised study. Lancet Oncol., 2011, 12(9), 852-861.
[http://dx.doi.org/10.1016/S1470-2045(11)70214-5 ] [PMID: 21862407]
[170]
Ledermann, J.; Harter, P.; Gourley, C.; Friedlander, M.; Vergote, I.; Rustin, G.; Scott, C.; Meier, W.; Shapira-Frommer, R.; Safra, T.; Matei, D.; Macpherson, E.; Watkins, C.; Carmichael, J.; Matulonis, U. Olaparib maintenance therapy in platinum-sensitive relapsed ovarian cancer. N. Engl. J. Med., 2012, 366(15), 1382-1392.
[http://dx.doi.org/10.1056/NEJMoa1105535 ] [PMID: 22452356]
[171]
Ang, J.E.; Gourley, C.; High, H.A.; Gore, M.E.; Kaye, S.B. Use of chemotherapy (CT) in BRCA1/2-deficient ovarian cancer (BDOC) patients (pts) with poly-ADP-ribose polymerase inhibitor (PARPi) resistance: a multi-institutional study. J. Clin. Oncol., 2012, •••, 30.
[172]
Kaye, S.B.; Lubinski, J.; Matulonis, U.; Ang, J.E.; Gourley, C.; Karlan, B.Y.; Amnon, A.; Bell-McGuinn, K.M.; Chen, L.M.; Friedlander, M.; Safra, T.; Vergote, I.; Wickens, M.; Lowe, E.S.; Carmichael, J.; Kaufman, B. Phase II, open-label, randomized, multicenter study comparing the efficacy and safety of olaparib, a poly (ADP-ribose) polymerase inhibitor, and pegylated liposomal doxorubicin in patients with BRCA1 or BRCA2 mutations and recurrent ovarian cancer. J. Clin. Oncol., 2012, 30(4), 372-379.
[http://dx.doi.org/10.1200/JCO.2011.36.9215 ] [PMID: 22203755]
[173]
Oza, A.M.; Cibula, D.; Oaknin, A.; Tchakov, I.; Friedlander, M. Olaparib plus paclitaxel plus carboplatin (P/C) followed by olaparib maintenance treatment in patients (pts) with platinum-sensitive recurrent serous ovarian cancer (PSR SOC): A randomized, openlabel phase II study. J. Clin. Oncol., 2012, 30(15), 5001-5001.
[http://dx.doi.org/10.1200/jco.2012.30.15_suppl.5001 ]
[174]
Dal Molin, G.Z.; Omatsu, K.; Sood, A.K.; Coleman, R.L. Rucaparib in ovarian cancer: an update on safety, efficacy and place in therapy. Ther. Adv. Med. Oncol., 2018, •••101758835918778483
[http://dx.doi.org/10.1177/1758835918778483 ] [PMID: 29977351]
[175]
Musella, A.; Bardhi, E.; Marchetti, C.; Vertechy, L.; Santangelo, G.; Sassu, C.; Tomao, F.; Rech, F.; D’Amelio, R.; Monti, M.; Palaia, I.; Muzii, L.; Benedetti Panici, P. Rucaparib: An emerging parp inhibitor for treatment of recurrent ovarian cancer. Cancer Treat. Rev., 2018, 66, 7-14.
[http://dx.doi.org/10.1016/j.ctrv.2018.03.004 ] [PMID: 29605737]
[176]
Caruso, D.; Papa, A.; Tomao, S.; Vici, P.; Panici, P.B.; Tomao, F. Niraparib in ovarian cancer: results to date and clinical potential. Ther. Adv. Med. Oncol., 2017, 9(9), 579-588.
[http://dx.doi.org/10.1177/1758834017718775 ] [PMID: 29081841]
[177]
Leijen, S.; van Geel, R.M.; Sonke, G.S.; de Jong, D.; Rosenberg, E.H.; Marchetti, S.; Pluim, D.; van Werkhoven, E.; Rose, S.; Lee, M.A.; Freshwater, T.; Beijnen, J.H.; Schellens, J.H. Phase II study of WEE1 inhibitor AZD1775 plus carboplatin in patients with TP53-mutated ovarian cancer re-fractory or resistant to first-line therapy within 3 months. J. Clin. Oncol., 2016, 34(36), 4354-4361.
[http://dx.doi.org/10.1200/JCO.2016.67.5942 ] [PMID: 27998224]
[178]
Lee, J.; Karzai, F.H.; Zimmer, A.; Annunziata, C.M.; Lipko-witz, S.; Parker, B.; Houston, N. Ekwede1, I.; Kohn, E.C. 8550 - A phase II study of the cell cycle checkpoint kinases 1 and 2 inhibitor (LY2606368; Prexasertib monomesylate monohydrate) in sporadic high-grade serous ovarian cancer (HGSOC) and germline BRCA mutation-associated ovarian cancer (gBRCAm? OvCa). Ann. Oncol., 2016, 27, 296-312.
[http://dx.doi.org/10.1093/annonc/mdw374.02]
[179]
Pujade-Lauraine, E. New treatments in ovarian cancer New treatments in ovarian cancer, 2017.
[180]
Moore, K.N.; Martin, L.P.; O’Malley, D.M.; Matulonis, U.A.; Konner, J.A.; Perez, R.P.; Bauer, T.M.; Ruiz-Soto, R.; Birrer, M.J. Safety and activity of mirvetuximab soravtansine (IMGN853), a folate receptor alpha-targeting antibody-drug conjugate, in platinum-resistant ovarian, fallopian tube, or primary peritoneal cancer: a phase I expansion study. J. Clin. Oncol., 2017, 35(10), 1112-1118.
[http://dx.doi.org/10.1200/JCO.2016.69.9538 ] [PMID: 28029313]
[181]
Rosenberg, B.; Vancamp, L.; Krigas, T. Inhibition of cell division in Escherichia coli by electrolysis products from a platinum electrode. Nature, 1965, 205, 698-699.
[http://dx.doi.org/10.1038/205698a0 ] [PMID: 14287410]
[182]
Guo, Z.; Sadler, P.J. Medicinal inorganic chemistry. Adv. Inorg. Chem., 1999, 49, 183-306.
[183]
Muhammad, N.; Guo, Z. Metal-based anticancer chemotherapeutic agents. Curr. Opin. Chem. Biol., 2014, 19, 144-153.
[http://dx.doi.org/10.1016/j.cbpa.2014.02.003 ] [PMID: 24608084]
[184]
Wheate, N.J.; Walker, S.; Craig, G.E.; Oun, R. The status of platinum anticancer drugs in the clinic and in clinical trials. Dalton Trans., 2010, 39(35), 8113-8127.
[http://dx.doi.org/10.1039/c0dt00292e ] [PMID: 20593091]
[185]
Wexselblatt, E.; Gibson, D. What do we know about the reduction of Pt(IV) pro-drugs? J. Inorg. Biochem., 2012, 117, 220-229.
[http://dx.doi.org/10.1016/j.jinorgbio.2012.06.013 ] [PMID: 22877926]
[186]
Kozubík, A.; Horváth, V.; Svihálková-Sindlerová, L.; Soucek, K.; Hofmanová, J.; Sova, P.; Kroutil, A.; Zák, F.; Mistr, A.; Turánek, J. High effectiveness of platinum(IV) complex with adamantylamine in overcoming resistance to cisplatin and suppressing proliferation of ovarian cancer cells in vitro. Biochem. Pharmacol., 2005, 69(3), 373-383.
[http://dx.doi.org/10.1016/j.bcp.2004.09.005 ] [PMID: 15652229]
[187]
Ott, I. On the medicinal chemistry of gold complexes as anti-cancer drugs. Coord. Chem. Rev., 2009, 253, 1670-1681.
[http://dx.doi.org/10.1016/j.ccr.2009.02.019]
[188]
Bindoli, A.; Rigobello, M.P.; Scutari, G.; Gabbiani, C.; Casini, A.; Messori, L. Thioredoxin reductase: a target for gold compounds acting as potential anticancer drugs. Coord. Chem. Rev., 2009, 253, 1692-1707.
[http://dx.doi.org/10.1016/j.ccr.2009.02.026]
[189]
Serratrice, M.; Edafe, F.; Mendes, F.; Scopelliti, R.; Zakeeruddin, S.M.; Grätzel, M.; Santos, I.; Cinellu, M.A.; Casini, A. Cytotoxic gold compounds: synthesis, biological characterization and investigation of their inhibition properties of the zinc finger protein PARP-1. Dalton Trans., 2012, 41(11), 3287-3293.
[http://dx.doi.org/10.1039/c2dt11913g ] [PMID: 22289927]
[190]
Marzano, C.; Gandin, V.; Folda, A.; Scutari, G.; Bindoli, A.; Rigobello, M.P. Inhibition of thioredoxin reductase by auranofin induces apoptosis in cisplatin-resistant human ovarian cancer cells. Free Radic. Biol. Med., 2007, 42(6), 872-881.
[http://dx.doi.org/10.1016/j.freeradbiomed.2006.12.021 ] [PMID: 17320769]
[191]
Ott, I.; Qian, X.; Xu, X.; Vlecken, D.H.; Marques, I.J.; Ku-bat, D.; Will, J.; Sheldrick, W.S.; Jesse, P.; Prokop, A.; Bagowski, C.P. Modulation of the biological properties of aspirin by formation of a bio organometallic derivative. Angew. Chem. Int. Ed., 2009, 48(6), 1160-1163.
[http://dx.doi.org/10.1002/anie.200803347]
[192]
Brana, M.F.; Ramos, A. Naphthalimides as Anticancer agents: synthesis and biological activity. Curr. Med. Chem., 2001, 1(3), 237-255.
[http://dx.doi.org/10.2174/1568011013354624 ] [PMID: 11172677]
[193]
Bruijnincx, P.C.; Sadler, P.J. New trends for metal complexes with anticancer activity. Curr. Opin. Chem. Biol., 2008, 12(2), 197-206.
[http://dx.doi.org/10.1016/j.cbpa.2007.11.013 ] [PMID: 18155674]
[194]
Ang, W.H.; Dyson, P.J. Classical and non-classical rutheni-um-based anticancer drugs: towards targeted chemotherapy. Eur. J. Inorg. Chem., 2006, 4003-4018.
[http://dx.doi.org/10.1002/ejic.200600723]
[195]
Liu, H.K.; Berners-Price, S.J.; Wang, F.; Parkinson, J.A.; Xu, J.; Bella, J.; Sadler, P.J. Diversity in guanine-selective DNA binding modes for an organometallic ruthenium arene complex. Angew. Chem. Int. Ed. Engl., 2006, 45(48), 8153-8156.
[http://dx.doi.org/10.1002/anie.200602873 ] [PMID: 17120267]
[196]
Habtemariam, A.; Melchart, M.; Fernandez, R.; Parsons, S.; Oswald, I.D.H.; Parkin, A.; Fabbiani, F.P.A.; Davidson, J.E.; Dawson, A.; Aird, R.E.; Jodrell, D.I.; Sadler, P.J. Structure-activity relationships for cytotoxic ruthenium(II) arene complexes containing N,N-, N,O-, and O,O-chelating ligands. J. Med. Chem., 2006, 49(23), 6858-6868.
[http://dx.doi.org/10.1021/jm060596m ] [PMID: 17154516]
[197]
Yan, Y.K.; Melchart, M.; Habtemariam, A.; Sadler, P.J. Organometallic chemistry, biology and medicine: ruthenium arene anticancer complexes. Chem. Commun. (Camb.), 2005, 38(38), 4764-4776.
[http://dx.doi.org/10.1039/b508531b ] [PMID: 16193110]
[198]
Das, S.; Batra, S.K. Understanding the unique attributes of MUC16 (CA125): potential implications in targeted therapy. Cancer Res., 2015, 75(22), 4669-4674.
[http://dx.doi.org/10.1158/0008-5472.CAN-15-1050 ] [PMID: 26527287]
[199]
Peacock, A.F.A.; Parsons, S.; Sadler, P.J. Tuning the hydrolytic aqueous chemistry of osmium arene complexes with N,O-chelating ligands to achieve cancer cell cytotoxicity. J. Am. Chem. Soc., 2007, 129(11), 3348-3357.
[http://dx.doi.org/10.1021/ja068335p ] [PMID: 17319668]
[200]
Ascierto, P.A.; Daniele, B.; Hammers, H.; Hirsh, V.; Kim, J.; Licitra, L.; Nanda, R.; Pignata, S. Perspectives in immunotherapy: meeting report from the “Immunotherapy Bridge”. J. Transl. Med., 2017, 15(1), 205.
[201]
Jelovac, D.; Armstrong, D.K. Role of farletuzumab in epithelial ovarian carcinoma. Curr. Pharm. Des., 2012, 18(25), 3812-3815.
[http://dx.doi.org/10.2174/138161212802002698 ] [PMID: 22591419]
[202]
Vergote, I.; Armstrong, D.; Scambia, G.; Teneriello, M.; Sehouli, J.; Schweizer, C.; Weil, S.C.; Bamias, A.; Fujiwara, K.; Ochiai, K.; Poole, C.; Gorbunova, V.; Wang, W.; O’Shannessy, D.; Herzog, T.J. A randomized, double-blind, placebo-controlled, phase III study to assess the efficacy and safety of weekly farletuzumab in combination with car-boplatin and taxane in patients with ovarian cancer in first platinum-sensitive relapse. J. Clin. Oncol., 2016, 34(19), 2271-2278.
[http://dx.doi.org/10.1200/JCO.2015.63.2596 ] [PMID: 27001568]
[203]
O’Malley, D.M.; Martinn, L.P.; Gilbert, L.; Iergote, I.; Matu-lonis, U.A.; Birrer, M.J.; Martin Castro, C.M.; Malek, K.S.; González-Martín, A.; Moore, K.N. Mirvetuximab so-ravtansine, a folate receptor alpha (FRα)-targeting antibody-drug conjugate (ADC), in combination with bevacizumab in patients (pts) with platinum-resistant ovarian cancer: Matur-ing safety and activity profile from the FORWARD II phase 1b study. J. Clin. Oncol., 2018, 36, 5549-5549.
[http://dx.doi.org/10.1200/JCO.2018.36.15_suppl.5549]
[204]
Bellone, S.; Buza, N.; Choi, J.; Zammataro, L.; Gay, L.; Elvin, J.; Rimm, D.L.; Liu, Y.; Ratner, E.S.; Schwartz, P.E.; Santin, A.D. Exceptional response to Pembrolizumab in a metastatic, chemotherapy/radiation-resistant ovarian cancer patient harboring a PD-L1-genetic rearrangement. Clin. Cancer Res., 2018, 24(14), 3282-3291.
[http://dx.doi.org/10.1158/1078-0432.CCR-17-1805 ] [PMID: 29351920]
[205]
Weber, M.M.; Fottner, C. Immune checkpoint inhibitors in the treatment of patients with neuroendocrine neoplasia. Oncol. Res. Treat., 2018, 41(5), 306-312.
[http://dx.doi.org/10.1159/000488996 ] [PMID: 29742518]
[206]
de Gramont, A.; Faivre, S.; Raymond, E. Novel TGF-β inhibitors ready for prime time in onco-immunology. OncoImmunology, 2016, 6(1)e1257453
[http://dx.doi.org/10.1080/2162402X.2016.1257453 ] [PMID: 28197376]
[207]
Senzer, N.; Barve, M.; Kuhn, J.; Melnyk, A.; Beitsch, P.; Lazar, M.; Lifshitz, S.; Magee, M.; Oh, J.; Mill, S.W.; Bedell, C.; Higgs, C.; Kumar, P.; Yu, Y.; Norvell, F.; Phalon, C.; Taquet, N.; Rao, D.D.; Wang, Z.; Jay, C.M.; Pappen, B.O.; Wallraven, G.; Brunicardi, F.C.; Shanahan, D.M.; Maples, P.B.; Nemunaitis, J. Phase I trial of “bi-shRNAi(furin)/GMCSF DNA/autologous tumor cell” vaccine (FANG) in advanced cancer. Mol. Ther., 2012, 20(3), 679-686.
[http://dx.doi.org/10.1038/mt.2011.269 ] [PMID: 22186789]
[208]
2018.
[209]
www.cancer.gov/publications/dictionaries/cancer-drug/def/immunotherapeutic-combination-product-cmb305
[210]
Deniger, D.C.; Pasetto, A.; Robbins, P.F.; Gartner, J.J.; Prickett, T.D.; Paria, B.C.; Malekzadeh, P.; Jia, L.; Yossef, R.; Langhan, M.M.; Wunderlich, J.R.; Danforth, D.N.; Somerville, R.P.T.; Rosenberg, S.A. T-cell responses to TP53 “Hotspot” mutations and unique neoantigens expressed by human ovarian cancers. Clin. Cancer Res., 2018, 24(22), 5562-5573.
[http://dx.doi.org/10.1158/1078-0432.CCR-18-0573 ] [PMID: 29853601]
[211]
Rump, A.; Morikawa, Y.; Tanaka, M.; Minami, S.; Umesaki, N.; Takeuchi, M.; Miyajima, A. Binding of ovarian cancer antigen CA125/MUC16 to mesothelin mediates cell adhesion. J. Biol. Chem., 2004, 279(10), 9190-9198.
[http://dx.doi.org/10.1074/jbc.M312372200 ] [PMID: 14676194]
[212]
Ayyoub, M.; Pignon, P.; Classe, J.M.; Odunsi, K.; Valmori, D. CD4+ T effectors specific for the tumor antigen NY-ESO-1 are highly enriched at ovarian cancer sites and coexist with, but are distinct from, tumor-associated Treg. Cancer Immunol. Res., 2013, 1(5), 303-308.
[http://dx.doi.org/10.1158/2326-6066.CIR-13-0062-T ] [PMID: 24777968]
[213]
Szender, J.B.; Papanicolau-Sengos, A.; Eng, K.H.; Miliotto, A.J.; Lugade, A.A.; Gnjatic, S.; Matsuzaki, J.; Morrison, C.D.; Odunsi, K. NY-ESO-1 expression predicts an aggressive phenotype of ovarian cancer. Gynecol. Oncol., 2017, 145(3), 420-425.
[http://dx.doi.org/10.1016/j.ygyno.2017.03.509 ] [PMID: 28392127]
[214]
Crompton, J.G.; Sukumar, M.; Roychoudhuri, R.; Clever, D.; Gros, A.; Eil, R.L.; Tran, E.; Hanada, K.; Yu, Z.; Palmer, D.C.; Kerkar, S.P.; Michalek, R.D.; Upham, T.; Leonardi, A.; Acquavella, N.; Wang, E.; Marincola, F.M.; Gattinoni, L.; Muranski, P.; Sundrud, M.S.; Klebanoff, C.A.; Rosenberg, S.A.; Fearon, D.T.; Restifo, N.P. Akt inhibition enhances expansion of potent tumor-specific lymphocytes with memory cell characteristics. Cancer Res., 2015, 75(2), 296-305.
[http://dx.doi.org/10.1158/0008-5472.CAN-14-2277 ] [PMID: 25432172]
[215]
Aref, S.; Bailey, K.; Fielding, A. Measles to the rescue: a review of oncolytic measles virus. Viruses, 2016, 8(10), 294-310.
[http://dx.doi.org/10.3390/v8100294 ] [PMID: 27782084]
[216]
Penheiter, A.R.; Russell, S.J.; Carlson, S.K. The sodium iodide symporter (NIS) as an imaging reporter for gene, viral, and cell-based therapies. Curr. Gene Ther., 2012, 12(1), 33-47.
[http://dx.doi.org/10.2174/156652312799789235 ] [PMID: 22263922]
[217]
Kristeleit, R.; Davidenko, I.; Shirinkin, V.; El-Khouly, F.; Bondarenko, I.; Goodheart, M.J.; Gorbunova, V.; Penning, C.A.; Shi, J.G.; Liu, X.; Newton, R.C.; Zhao, Y.; Maleski, J.; Leopold, L.; Schilder, R.J. A randomised, open-label, phase 2 study of the IDO1 inhibitor epacadostat (INCB024360) versus tamoxifen as therapy for biochemically recurrent (CA-125 relapse)-only epithelial ovarian cancer, primary peritoneal carcinoma, or fallopian tube cancer. Gynecol. Oncol., 2017, 146(3), 484-490.
[http://dx.doi.org/10.1016/j.ygyno.2017.07.005 ] [PMID: 28698009]
[218]
Spira, A.I.; Hamid, O. Efficacy/safety of epacadostat plus pembrolizumab in triple-negative breast cancer and ovarian cancer: Phase I/II ECHO-202 study. J. Clin. Oncol., 2017, 35(15), 1103-1103.
[http://dx.doi.org/10.1200/JCO.2017.35.15_suppl.1103 ]
[219]
Mitchell, T.C.; Hamid, O.; Smith, D.C.; Bauer, T.M.; Was-ser, J.S.; Olszanski, A.J.; Luke, J.J.; Balmanoukian, A.S.; Schmidt, E.V.; Zhao, Y.; Gong, X.; Maleski, J.; Leopold, L.; Gajewski, T.F. Epacadostat plus pembrolizumab in patients ITH advanced sol-id tumors: phase I results from a multicenter, open-label phase I/II trial (ECHO-202/KEYNOTE-037). J. Clin. Oncol., 2018, 36(32), 3223-3230.
[220]
https://clinicaltrials.gov/ct2/show/NCT025758072018
[221]
Ibanez de Caceres, I.; Battagli, C.; Esteller, M.; Herman, J.G.; Dulaimi, E.; Edelson, M.I.; Bergman, C.; Ehya, H.; Eisenberg, B.L.; Cairns, P. Tumor cell-specific BRCA1 and RASSF1A hypermethylation in serum, plasma, and peritoneal fluid from ovarian cancer patients. Cancer Res., 2004, 64(18), 6476-6481.
[http://dx.doi.org/10.1158/0008-5472.CAN-04-1529 ] [PMID: 15374957]
[222]
Gloss, B.; Moran-Jones, K.; Lin, V.; Gonzalez, M.; Scurry, J.; Hacker, N.F.; Sutherland, R.L.; Clark, S.J.; Samimi, G. ZNF300P1 encodes a lincRNA that regulates cell polarity and is epigenetically silenced in type II epithelial ovarian cancer. Mol. Cancer, 2014, 13(3), 3.
[http://dx.doi.org/10.1186/1476-4598-13-3 ] [PMID: 24393131]
[223]
Shen, H.; Fridley, B.L.; Song, H.; Lawrenson, K.; Cunning-ham, J.M.; Ramus, S.J. Epigenetic analysis leads to identification of HNF1B as a subtype-specific susceptibility gene for ovarian cancer. Nat. Commun., 2013, 4(1628), 1-10.
[http://dx.doi.org/10.1038/ncomms2629 ] [PMID: 23535649]
[224]
Makarla, P.B.; Saboorian, M.H.; Ashfaq, R.; Toyooka, K.O.; Toyooka, S.; Minna, J.D.; Gazdar, A.F.; Schorge, J.O. Promoter hypermethylation profile of ovarian epithelial neoplasms. Clin. Cancer Res., 2005, 11(15), 5365-5369.
[http://dx.doi.org/10.1158/1078-0432.CCR-04-2455 ] [PMID: 16061849]
[225]
Agrawal, K.; Das, V.; Vyas, P.; Hajdúch, M. Nucleosidic DNA demethylating epigenetic drugs - A comprehensive review from discovery to clinic. Pharmacol. Ther., 2018, 188, 45-79.
[http://dx.doi.org/10.1016/j.pharmthera.2018.02.006 ] [PMID: 29454856]
[226]
Bitler, B.G.; Aird, K.M.; Garipov, A.; Li, H.; Amatangelo, M.; Kossenkov, A.V.; Schultz, D.C.; Liu, Q.; Shih, IeM.; Conejo-Garcia, J.R.; Speicher, D.W.; Zhang, R. Synthetic lethality by targeting EZH2 methyltransferase activity in ARID1A-mutated cancers. Nat. Med., 2015, 21(3), 231-238.
[http://dx.doi.org/10.1038/nm.3799 ] [PMID: 25686104]
[227]
Kim, H-J.; Bae, S-C. Histone deacetylase inhibitors: molecular mechanisms of action and clinical trials as anti-cancer drugs. Am. J. Transl. Res., 2011, 3(2), 166-179.
[PMID: 21416059]
[228]
Bitler, B.G.; Wu, S.; Park, P.H.; Hai, Y.; Aird, K.M.; Wang, Y.; Zhai, Y.; Kossenkov, A.V.; Vara-Ailor, A.; Rauscher, F.J., III; Zou, W.; Speicher, D.W.; Huntsman, D.G.; Conejo-Garcia, J.R.; Cho, K.R.; Christianson, D.W.; Zhang, R. ARID1A-mutated ovarian cancers depend on HDAC6 activity. Nat. Cell Biol., 2017, 19(8), 962-973.
[http://dx.doi.org/10.1038/ncb3582 ] [PMID: 28737768]
[229]
Fukumoto, T.; Park, P.H.; Wu, S.; Fatkhutdinov, N.; Karakashev, S.; Nacarelli, T.; Kossenkov, A.V.; Speicher, D.W.; Jean, S.; Zhang, L.; Wang, T.L.; Shih, I.M.; Conejo-Garcia, J.R.; Bitler, B.G.; Zhang, R. Repurposing Pan-HDAC inhibitors for ARID1A-mutated ovarian cancer. Cell Rep., 2018, 22(13), 3393-3400.
[http://dx.doi.org/10.1016/j.celrep.2018.03.019 ] [PMID: 29590609]
[230]
Chiappinelli, K.B.; Strissel, P.L.; Desrichard, A.; Li, H.; Henke, C.; Akman, B.; Hein, A.; Rote, N.S.; Cope, L.M.; Snyder, A.; Makarov, V.; Budhu, S.; Slamon, D.J.; Wolchok, J.D.; Pardoll, D.M.; Beckmann, M.W.; Zahnow, C.A.; Merghoub, T.; Chan, T.A.; Baylin, S.B.; Strick, R. Inhibiting DNA methylation causes an interferon response in cancer via dsRNA including endogenous retroviruses. Cell, 2015, 162(5), 974-986.
[http://dx.doi.org/10.1016/j.cell.2015.07.011 ] [PMID: 26317466]
[231]
Stone, M.L.; Chiappinelli, K.B.; Li, H.; Murphy, L.M.; Travers, M.E.; Topper, M.J.; Mathios, D.; Lim, M.; Shih, I.M.; Wang, T.L.; Hung, C.F.; Bhargava, V.; Wiehagen, K.R.; Cowley, G.S.; Bachman, K.E.; Strick, R.; Strissel, P.L.; Baylin, S.B.; Zahnow, C.A. Epigenetic therapy activates type I interferon signaling in murine ovarian cancer to reduce immunosuppression and tumor burden. Proc. Natl. Acad. Sci. USA, 2017, 114(51), E10981-E10990.
[http://dx.doi.org/10.1073/pnas.1712514114 ] [PMID: 29203668]
[232]
Ahluwalia, A.; Yan, P.; Hurteau, J.A.; Bigsby, R.M.; Jung, S.H.; Huang, T.H.; Nephew, K.P. DNA methylation and ovarian cancer. I. Analysis of CpG island hypermethylation in human ovarian cancer using differential methylation hybridization. Gynecol. Oncol., 2001, 82(2), 261-268.
[http://dx.doi.org/10.1006/gyno.2001.6291 ] [PMID: 11531277]
[233]
Fu, S.; Hu, W.; Iyer, R.; Kavanagh, J.J.; Coleman, R.L.; Levenback, C.F. Phase IbIIa study to reverse platinum re-sistance by the use of a hypomethylating agent azacitidine in platinum-resistant or refractory epithelial ovarian cancer. Cancer, 2011, 117, 1661-1669.
[http://dx.doi.org/10.1002/cncr.25701 ] [PMID: 21472713]
[234]
Nervi, C.; De Marinis, E.; Codacci-Pisanelli, G. Epigenetic treatment of solid tumors: a review of clinical trials. Clin. Epigenetics, 2015, 7, 127.
[http://dx.doi.org/10.1186/s13148-015-0157-2 ] [PMID: 26692909]
[235]
Matulonis, U.A.; Oza, A.M.; Ho, T.W.; Ledermann, J.A. Intermediate clinical endpoints: a bridge between progression-free survival and overall survival in ovarian cancer trials. Cancer, 2015, 121(11), 1737-1746.
[http://dx.doi.org/10.1002/cncr.29082 ] [PMID: 25336142]
[236]
Matei, D.; Fang, F.; Shen, C.; Schilder, J.; Arnold, A.; Zeng, Y.; Berry, W.A.; Huang, T.; Nephew, K.P. Epigenetic resensitization to platinum in ovarian cancer. Cancer Res., 2012, 72(9), 2197-2205.
[http://dx.doi.org/10.1158/0008-5472.CAN-11-3909 ] [PMID: 22549947]
[237]
Moufarrij, S.; Dandapani, M.; Arthofer, E.; Gomez, S.; Srivastava, A.; Lopez-Acevedo, M.; Villagra, A.; Chiappinelli, K.B. Epigenetic therapy for ovarian cancer: promise and progress. Clin. Epigenetics, 2019, 11(1), 7.
[http://dx.doi.org/10.1186/s13148-018-0602-0 ] [PMID: 30646939]
[238]
Zhang, Z.; Ma, P.; Jing, Y.; Yan, Y.; Cai, M-C.; Zhang, M.; Zhang, S.; Peng, H.; Ji, Z.L.; Di, W.; Gu, Z.; Gao, W.Q.; Zhuang, G. BET Bromodomain inhibition as a therapeutic strategy in ovarian cancer by downregulating FoxM1. Theranostics, 2016, 6(2), 219-230.
[http://dx.doi.org/10.7150/thno.13178 ] [PMID: 26877780]
[239]
Yang, L.; Zhang, Y.; Shan, W.; Hu, Z.; Yuan, J.; Pi, J.; Wang, Y.; Fan, L.; Tang, Z.; Li, C.; Hu, X.; Tanyi, J.L.; Fan, Y.; Huang, Q.; Montone, K.; Dang, C.V.; Zhang, L. Repression of BET activity sensitizes homologous recombination-proficient cancers to PARP inhibition. Sci. Transl. Med., 2017, 9(400), 1-22.
[http://dx.doi.org/10.1126/scitranslmed.aal1645 ] [PMID: 28747513]
[240]
Hilpert, F.; Du Bois, A. Patient-reported outcomes in ovarian cancer: are they key fac-tors for decision making? Expert Rev. Anticancer Ther., 2018, 18, 3-7.
[http://dx.doi.org/10.1080/14737140.2018.1516146]

Rights & Permissions Print Cite
Article Metrics
26
1
© 2024 Bentham Science Publishers | Privacy Policy